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ANOVA Analysis of variance  
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bp   Base pair  
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CRISPR-Cas Clustered Regularly Interspaced Short Palindromic Repeats – CRISPR associated 
protein 
CRISPR-Cas9 Clustered Regularly Interspaced Short Palindromic Repeats – CRISPR associated 
protein 9 
crRNA  CRISPR-RNA  
DSB Double strand break  
dsDNA Double-stranded DNA 
E. coli  Escherichia coli  
EDTA Ethylenediaminetetraacetic acid  
ETC Electron transport chain  
FACS Fluorescence activated cell sorting  
FADH2 Flavin adenine dinucleotide  
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FIMM Institute for Molecular Medicine Finland 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFP Green fluorescent protein  
gRNA Guide RNA 
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iPSC Induced pluripotent stem cell 
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mt-DNA Mitochondrial DNA  
mTOR Mammalian target of rapamycin 
MTS Mitochondrial targeting sequence 
NADH Nicotinamide adenine dinucleotide  
Nanog Homeobox protein Nanog 
NHEJ Non-homologous end joining  
nt Nucleotide 
Oct4 Octamer-binding transcription factor 4  
OXPHOS Oxidative phosphorylation  
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PPi Pyrophosphate  
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PVDF Polyvinylidene difluoride  
p53 Cellular tumour antigen p53 
RC Respiratory chain  
RNAi RNA interference 
RNP Ribonucleoprotein 
ROCK p160 Rho-associated coiled-coil kinase  
ROS Reactive oxygen species 
RT Room temperature 
RT-qPCR Real-time quantitative polymerase chain reaction  
rRNA Ribosomal RNA 
SARS2  Mitochondrial seryl tRNA-synthetase gene 
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sgRNA  Single guide RNA  
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spCas9              Streptococcus pyogenes CRISPR associated protein 9 
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TRA1-60          TRA-1-60 antibody 
TRA1-81          TRA-1-81 antibody  
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1.1 Mitochondria  
Mitochondria (singular mitochondrion) are membrane-bound organelles found in the cytoplasm of 
most eukaryotic cells. They can be tubular, round, or irregular shaped due to developmental 
perturbations. Mitochondria contain a double membrane of a permeable outer membrane and a highly 
folded inner membrane with an intermembrane space between them. The space enclosed by the inner 
membrane is called the matrix. Mitochondria have their unique transcriptional and translational 
machineries, and a unique circular genome (mitochondrial DNA, mtDNA) in the matrix containing 37 
genes, 13 of which encode for components of the respiratory chain (RC) along with 2 rRNAs and 22 
tRNAs (Anderson et al., 1981). The number of mitochondria in a cell depends on the cell-type 
specific metabolic needs, with most cells containing hundreds. Mitochondria are constantly 
undergoing fission and fusion to replicate. Their high replication rate makes mtDNA susceptible to a 
higher mutation rate than nuclear DNA. Damage to mitochondrial networks is especially problematic 
for long-lived post-mitotic cells like neurons, cardiomyocytes, renal tubular cells, and pancreatic islet 
cells (reviewed in Yaffe, 1999; Van der Bliek, Sedensky & Morgan, 2017). 
The primary function of mitochondria is to produce energy for cellular and mechanical functions in 
the form of adenosine triphosphate (ATP) from sugars, fats, and other chemicals with the help of 
molecular oxygen. The major source of ATP is through oxidative phosphorylation (OXPHOS), where 
ATP is synthesised in the inner mitochondrial membrane through the electron transport chain (ETC), 
which is the transfer of electrons from NADH or FADH2 to O2 by a series of electron carriers. 
OXPHOS complexes I-IV form the ETC, and complex V is ATP synthase. Electrons are transported 
through acceptor proteins with serially higher reduction ability at the ETC complexes by a series of 
redox reactions and finally passed to O2. The transport of electrons creates a proton gradient across the 
inner mitochondrial membrane, which creates a pH gradient and transmembrane electrical force, 
resulting in proton-motive force and finally phosphoryl transfer potential. The flow of protons back to 
the matrix is used by ATP synthase to phosphorylate ADP to create ATP (reviewed in Chan, 2006). 
As an additional by-product of OXPHOS, reactive oxygen species (ROS) are formed when an 
electron bypasses any of the ETC complexes, and oxygen is incompletely reduced. In normal 
amounts, ROS partake in cell signalling. In addition to ATP production, mitochondria play an 
important role for example in calcium storage and homeostasis for cell signalling activities, ROS 
signalling, iron-sulphur cluster and haem synthesis, and regulating cell growth and apoptosis (Craven 
et al., 2017; Ylikallio & Suomalainen, 2012).   
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 1.2 Mitochondrial tRNA-synthetases (mt-aaRS) in health and mitochondrial 
disease 
Humans have two distinct sets of essential nuclear-encoded aminoacyl tRNA-synthetases (aaRSs), the 
cytosolic- and mitochondrial aaRS. The genes for mitochondrial aaRS, or mt-aaRS are denoted with a 
2 at the end of aaRS name, e.g. ‘SARS2’. Their canonical role is as enzymes in the attachment of an 
amino acid into their isoaccepting cognate tRNAs. Each of the 19 aaRS and 19 mt-aaRS for each of 
the 20 amino acids act in a two-step reaction, first activating a single amino acid (aa) via an adenylate 
intermediate, and second covalently linking it to one of the ribose hydroxyls at the 3’ end of a set of 
tRNA isoacceptors: 
ATP + aa ⇄ aa – AMP +PPi (inorganic pyrophosphate)  (1) 
Aa – AMP + tRNAAA à aa - tRNAAA + AMP                      (2)  
Once the tRNA is charged, a ribosome can transfer the amino acid from the tRNA into a position a 
growing peptide according to the anticodon of the tRNA. All mt-aaRSs are encoded by nuclear genes 
and synthesised in the cytosol, from where transportation to mitochondria occurs with the help of 
mitochondrial targeting sequence (MTS), which is cleaved off during entry to mitochondria (Figure 
1). Mitochondrial aminoacyl tRNA synthetases can be categorised into two classes I and II based on 
their domain architecture and tRNA binding modes. Class I synthetases contain a characteristic 
Rossmann fold catalytic domain and are mostly monomeric. Class II synthetases have anti-parallel 
beta-sheet folds flanked by alpha helices, are mostly dimeric or multimeric, and contain at least three 




                      
Figure 1. The localisation and canonical functions of mt-aaRS in mitochondrial translation, and 
the main organ systems affected by pathogenic mutations. Human mt-aaRS are nuclear encoded, 
synthesised in the cytosol, and delivered into the mitochondria by mitochondrial targeting sequence 
(MTS), which is cleaved upon entry to mitochondria. aaRS participate in mitochondrial translation. 
Tissue types and organs requiring high ATP amounts, such as nervous, muscular, cardiovascular, and 
urinary systems, are more severely affected by mutations in mt-aaRS genes (Figure source: Sissler, 
González-Serrano & Westhof, 2017).  
Mitochondrial diseases refer to a genetically and clinically heterogenous group of disorders caused by 
OXPHOS dysfunction, that altogether make up the most common inherited metabolic diseases with a 
prevalence of 1:5000 (Diodato, Ghezzi & Tiranti, 2014). Inherited mitochondrial diseases can arise 
from mutations nuclear DNA or from the maternally inherited mtDNA. They can arise sporadically, 
or follow autosomal, recessive, maternal, or X-linked forms of inheritance (Suomalainen and 
Battersby, 2017). Mitochondrial diseases can manifest in all cells of the body except mature red blood 
cells, and most commonly in tissues with high energy expenditure (Craven et al., 2016). They can 
occur through defects in mitochondrial gene expression, nuclear-mitochondrial crosstalk, mtDNA 
maintenance, or mitochondrial stress responses, among other reasons (Suomalainen & Battersby, 
2017). The expression of mtDNA in addition to the nuclear encoded DNA partaking in OXPHOS are 
crucial for OXPHOS assembly and function and maintaining overall cellular homeostasis. Defects in 
OXPHOS cause mitochondrial dysfunction and energy production impairment (Anderson et al., 
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1981). In addition to ATP deficiencies, characteristics of mitochondrial disorders include systemic 
drop in pH caused by increased plasma lactate levels. OXPHOS dysfunction can lead to an elevated 
NADH/NAD ratio due to the inability of the citric acid cycle to feed forward NADH to the electron 
transport chain. Pyruvate levels are also increased by inhibition of the citric acid cycle. The elevated 
NADH/NAD ratio and increased pyruvate levels to shift the NADH-dependent lactate dehydrogenase 
towards production of lactate (Ylikallio & Suomalainen, 2012). Additionally, phenotype-specific 
signs can include ragged red fibres in muscle, exercise intolerance, or neurological problems, which 
are found in biochemical and histopathologic and exercise tolerance examinations in the clinic 
(Ognjenović & Simonović, 2017).  
Several mitochondrial diseases involving mitochondrial protein synthesis and quality control 
deficiencies are caused by mutations in all of the nuclear encoded mt-aaRS. Defects in mt-aaRS 
involve either homozygous or compound heterozygous mutations, resulting in autosomal recessive 
disorders presenting as isolated clinical signs or syndromes, sometimes with overlapping clinical 
presentations (González-Serrano, Chihade & Sissler, 2019; Ognjenović & Simonović, 2017). 
Mutations in the synthetases cause depletion of charged tRNAs on ribosomes, resulting in translation 
interruptions causing OXPHOS assembly defects (Suomalainen & Battersby, 2017). Although all 19 
mt-aaRS have the same biochemical function of charging tRNAs with their cognate amino acids 
(aminoacylation), mutations in different mt-aaRS lead to very different disease phenotypes of varying 
severity in different tissue types, presenting in various stages of life (Nunnari & Suomalainen, 2012) 
In addition to mt-aaRS mutations, mt-tRNA mutations exist causing an even wider variety of 
phenotypes (González-Serrano, Chihade & Sissler, 2019). These variables make them difficult to 
study (Ylikallio & Suomalainen, 2012), and no cures exist with treatment centred around relieving 
symptoms and treating complications (Suomalainen, 2011; Gorman et al., 2016). Mutations in mt-
aaRS can cause tissue-specific or multi-organ syndromes almost exclusively affecting the central and 
peripheral nervous systems, and other organ systems with high mitochondria number and high ATP 
demand like musculoskeletal, cardiovascular, and urinary (Sissler, González-Serrano & Westhof, 
2017; Vafai & Mootha, 2012).  
Even mutations in one mt-aaRS gene can cause disparate phenotypes. For example, homozygous 
mutations in the gene SARS2 coding for mitochondrial seryl-tRNA synthetase leading to amino acid 
changes p.D390G or p.R402H in the aminoacylation domain of the protein cause HUPRA syndrome 
(hyperuricemia, pulmonary hypertension, renal failure in infancy, and alkalosis) (Belostotsky et al., 
2011; Rivera et al., 2013), but a splicing variant c.1347 G>A in SARS2 causes spastic paresis 
(Linnankivi et al., 2016). Different alanyl-tRNA synthetase mutations have been linked to 
cardiomyopathy, or leukoencephalopathy, among others (Sissler, González-Serrano & Westhof, 2017; 
Götz et al., 2011). Pathogenic mutations in these enzymes can be studied in their downstream 
consequences, such as mitochondrial respiratory chain deficiencies, OXPHOS deficiency, or defective 
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mitochondrial protein synthesis. Disease mechanisms are also studied through consequences of 
mutations on protein architecture and resulting defects in functional domains (Moulinier et al., 2017). 
Since many of the mt-aaRS mutations are not comparable, i.e. they affect the synthetases differently, 
variation in tissue- and organ specificity may be dependent on which an amino acid residue is affected 
and to what extent aminoacylation is compromised as a result (Diodato, Ghezzi & Tiranti, 2014). 
Some mt-aaRS contain an editing domain in addition to the canonical aminoacylation core domains. 
The role of the editing domain is to prevent the mischarging of a tRNA by deacylating any wrong 
amino acids either pre- or post- transfer (Schimmel & Schmidt, 1995; Hilander et al., 2017). Not all 
mt-aaRS contain an editing domain, for example SARS2, so mutations in other domains of the 
synthetase may be the cause of disease phenotypes. tRNA-charging defects, for example due to 
unstable catalytic function, have been suggested as the cause for disturbed mt-aaRS enzyme activity 
(Belostotsky et al., 2011). Reasons for variable age-of-onset are not known, but systemic involvement 
and more severe brain abnormalities are more prevalent in early-onset cases, and as reported in 
AARS2 leukoencephalopathy (Fine et al., 2019).  
Mechanisms behind phenotype variability have been suggested. While non-canonical functions of mt-
aaRS are poorly known, it is suggested that non-canonical, non-translational functions (e.g. immune 
response, inflammation, mTOR, IFN-γ and p53 signalling, neuronal differentiation) may play a role in 
phenotype heterogeneity of mt-aaRS mutations (Guo & Schimmel, 2013; Fine et al., 2019). Given the 
canonical function of mt-aaRSs to bind amino acids to their cognate tRNA, it can be expected that 
pathogenic mutations impair this pathway for example by reducing tRNA charging. Differences in 
mitochondrial chaperone activities between tissue types can affect the stability of some mutants 
(Konovalova & Tyynismaa, 2013). In neurons, the unique cell morphology and protein quality check 
may make them vulnerable to malfunction when parts of the protein quality check machinery are 
faulty (González-Serrano, Chihade & Sissler, 2019). Progressive phenotypes could be explained by 
faulty protein import, protein folding, or accumulation of misfolded and unfolded proteins that lead to 
endoplasmic reticulum (ER) stress and abnormal activation of unfolded protein response (UPR) and 
mitochondrial unfolded protein response (UPRmt) (Rolland et al., 2019; Wang & Kaufman, 2016). 
Although reasons for heterogeneity of phenotypes and molecular mechanisms of mt-aaRS mutations 
have been hypothesised and even partly explained, disease modelling of the pathogenic genotypes and 
the functional analyses of their downstream consequences is required (González-Serrano, Chihade & 




 1.3 Mitochondrial seryl-tRNA synthetase 
SARS2 is a protein coding gene on chromosome 19 encoding for mitochondrial seryl-tRNA synthetase 
that contains 16 exons and spans 15.1 kb (structure shown in Figure 2 A). It belongs to the class II 
aminoacyl tRNA synthetase family, that are mostly dimeric or multimeric with an anti-parallel beta-
sheet flanked by alpha helices. The aminoacyl group is coupled to the 3’-hydroxyl site of the tRNA.  
The product is a 518 amino-acid protein that weighs 58 kDa (Figure 2 B). Specifically, it provides 
serine aminoacylation to two mitochondrial tRNAs, tRNA-ser (AGY) and tRNA-ser (UCN) by 
catalysing the esterification of seryl to both compatible tRNAs to form an aminoacyl-tRNA. tRNA-ser 
(AGY) is a small mitochondrial tRNA, completely lacking the D-domain (Steinberg et al., 1994).  
      A.  
                          
B. 
          
Figure 2. A. The SARS2 gene encoding mitochondrial seryl-tRNA synthetase, containing 16 exons 
(Linnankivi et al., 2016), including the mutations that have been identified and associated phenotypes. 





 1.4 SARS2 patient genetics and clinical phenotype 
Linnankivi, Neupane, Richter et al. in 2016, reported that a patient presenting with a severe 
childhood-onset spastic paresis had a homozygous single nucleotide variant c.1347 G>A in the last 
nucleotide of exon 14 of seryl tRNA-synthetase. The mutation was revealed by the MGZ 
Mitochondrial Diseases Multi Gene Panel (ID 87.01) containing 168 genes. Spastic paresis refers 
generally to an increased muscle tonus and tendon reflexes, and partial loss of voluntary movement. 
The nucleotide change causes a frameshift after exon 14 that completely changes the C-terminus 
amino acid sequence and results in a premature stop codon. The expected abnormal protein is 510 
amino acids, compared to the normal, which is 518. The parents of the patient were heterozygous for 
the same mutation (Figure 3) and healthy. The altered C-terminus of the synthetase was shown to 
severely compromise tRNA charging and affect tRNA-ser (AGY) specifically. Western blot revealed 
a clear reduction in SARS2 protein level in patient fibroblasts to just 5% of the level in normal 
fibroblasts, but no changes in the cytochrome C oxidase subunit 1 and 2 (COX1 and COX2) proteins 
of respiratory complex IV encoded by mtDNA. Mitochondrial protein synthesis was normal 
(Linnankivi et al., 2016).  
The patient’s genotype and phenotype differ markedly from the previously reported homozygous 
SARS2 missense mutations in exon 13 c.1169A>G resulting in p.D390G, and c.1205G>A resulting in 
p.R402H (Belostotsky et al., 2011; Rivera et al., 2013) causing HUPRA syndrome. HUPRA 
syndrome is a multisystem phenotype characterised by progressive renal failure in infancy leading to 
electrolyte imbalances, metabolic alkalosis, pulmonary hypertension, hypotonia, and delayed 
development (Belostotksy et al., 2011). While both mutations have destabilising effects on tRNA-ser 
(AGY) isoacceptors, the SARS2 patients with HUPRA syndrome were reported to have only 10-20% 
of the normal amount of tRNA-ser (AGY) in lymphocyte culture, while the spastic paresis patient had 
levels of tRNA-ser (AGY) reduced to 40% of normal fibroblasts. The differential level of stable 
tRNA-ser (AGY) and the resulting failure of SARS2 to aminoacylate tRNA-ser (AGY) leading to its 
degradation may be an explaining factor behind the large phenotype differences (Linnankivi et al., 
2016). 
The patient’s development was normal until age 7-8 months, when the first signs of increased muscle 
tone in the legs were noticed. By age 5, spasticity progressed to involve upper extremities and oral 
motorics. While MRI at 1 year of age already showed a T2 signal increase in dentate nuclei, atrophy 
of cerebellar hemispheres and vermis were present at 5 years of age. Thalamic MR spectroscopy at 7 
years of age showed elevated lactate levels. Muscle biopsy and respiratory chain enzymes were 
normal. Kidneys appeared normal in an abdominal ultrasound, but a liver biopsy showed mild 
steatosis. Blood-count, acid-base balance, electrolytes, plasma creatinine, cystatin C, uric acid, 
phosphate and parathormone levels were normal. Also, blood lactate, pyruvate, and urine organic and 
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amino acids were normal. Neuropsychological assessment at 8 years of age indicated cognitive 
developmental level of a 4.5-year-old. Since age 10 in 2016 the patient has had severe spastic 
tetraparesis.  
                                               
Figure 3. Sequencing traces of the patient’s and parents’ DNA compared against a normal healthy 
individual to show the splicing variant c.1347 G>A in SARS2 (source: Linnankivi et al., 2016).  
 1.5 Induced pluripotent stem cells in disease modelling  
Induced pluripotent stem cells (iPSC) are stem cells that have been reprogrammed from differentiated 
somatic cells back to a pluripotent stem cell state. iPSC resemble embryonic stem cells and can by 
definition differentiate into any cell type of the three embryonic germ layers (endoderm, mesoderm, 
ectoderm), and maintain the ability to proliferate indefinitely in culture. While embryonic stem cells 
originate from pre-gastrula embryos, limiting their use in research due to ethical concerns, iPSC 
overcome these issues. iPSC form into dense colonies with clear borders. The first reprogramming 
was reported in 2006, when Shinya Yamanaka’s lab generated iPSC from embryonic and adult 
fibroblasts of mice by the activation of four genes encoding transcription factors, c-Myc, Oct3/4, Sox2 
and Klf4 (Takahashi & Yamanaka, 2006). In 2007, the lab reprogrammed the first human iPSC using 
the same transcription factors (Takahashi et al., 2007). The applications of iPSC include disease 
modelling, regenerative medicine as autologous cell transplants without immune rejection concerns, 
and drug candidate and drug toxicity screening (Sterneckert, Reinhardt & Schöler, 2014; Wiegand & 
Banerjee, 2019; Lorenz et al., 2017). The use of isogenic iPSC in drug candidate screening is 
promising due to their possibility to reveal drug efficiency concerning the mutation of interest 
(Robinton & Daley, 2012; Barral & Kurian, 2016).  
iPSC have been increasingly used since the 2010s for disease modelling of genetic diseases, 
especially ones with unknown molecular disease mechanisms. iPSC are an especially important model 
system for neuronal and cardiac phenotypes, where extraction of primary tissue is difficult and 
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harmful (Bellin et al., 2012). The standard of disease modelling is that a model is based on a known 
genetic lesion in a specific organism, represents the phenotypes present, and can model clinical 
manifestations and comorbidities (Doss & Sachinidis, 2019). Considering these validity parameters, 
iPSC disease models provide an advantage over patient primary cells because it is possible to create 
cell type-specific models that contain patient-specific genetic background without the need for 
invasive and many times impossible sample collection, or collection of large amounts of patient cells 
(Sterneckert, Reinhardt & Schöler, 2014; Bassett, 2017). To ensure their validity as stem cells, newly 
reprogrammed iPSC and cell lines created from them are subjected to quality control analyses. These 
include measuring pluripotency by the presence and quantity of surface markers TRA1-60, TRA1-81, 
SSEA3 and SSEA4, and/or transcription factors such as OCT4, SOX2, NANOG and LIN28A 
(O’Malley et al., 2013; Loh et al., 2006; Yu et al., 2007).  
Differentiation methods that utilise knowledge of endogenous developmental pathways that lead to a 
certain cell type are being developed and used, especially for neurons, cardiomyocytes and pancreatic 
β-cells (Du et al., 2015; Yoshida & Yamanaka, 2017; Balboa et al., 2018). It also holds promise for 
studying complex phenotypes such as multi-system syndromes, in that they can establish whether the 
mutation of interest is responsible for the defects in different cell- or tissue types (Soldner et al., 2011; 
Yusa et al., 2011; Hockemeyer & Jaenisch, 2017). Such defects can be studied using genome 
engineering of a patient mutation in a parental cell line. In addition to knocking in a gene variant of 
interest in an isogenic cell line, the mutation in patient iPSC can be similarly corrected using genome 
editing. Patient mutations that have been corrected to be healthy should then behave like wild type 
cells (Sterneckert, Reinhardt & Schöler, 2014; Giacalone et al., 2018).  
Other reprogramming methods are under development in order to improve pluripotency and thereby 
reliability, validity and efficiency of disease modelling pipelines. Human iPSC have most commonly 
been reprogrammed from fibroblasts or blood cells due to their availability and non-invasiveness of 
sampling. However, iPSC and cells differentiated from them may sometimes retain characteristics of 
cells of foetal origin (Hrvatin et al., 2014), and can contain epigenetic features of the cell of origin 
(Kim et al., 2010). However, more recently it has been found that epigenetic effects on cellular state 
are minimal, and isogenic iPSC from fibroblasts and blood cells have similar differentiation 
propensities (Kyttälä et al., 2016). In addition to retroviral delivery of the four key transcription 
factors in 2006, adenoviral gene delivery, microRNAs, RNA interference (RNAi), use of small 
molecules to replace the introduction of transcription factors into cells, and CRISPRa based 
endogenous promoter activation are other iPSC reprogramming methods that hold potential in 




 1.6 The creation and significance of isogenic control clonal cell lines 
One iPSC disease modelling approach in studying the effect of genotype on the disease phenotype is 
using isogenic disease models, which are selected or engineered to model the genetics specific to a 
patient- or patient population in vitro. Isogenic disease models are used as controls in analyses of 
genotype-phenotype relationships (Avior, Sagi & Benvenisty, 2016). Patient iPSC and primary cell 
populations may contain background genetic variation that may mask subtle phenotypes, in addition 
to the disease mutation of interest revealed by gene panels or Whole Exome/Whole Genome 
sequencing. Creating the mutation of interest in a healthy control cell line allows characterisation of 
the significance of the mutation of interest on a phenotype in a more precise manner (Bassett, 2017). 
Discovering the role and importance of genes and proteins in different cell types can be important for 
the characterisation of their basic functions and their roles in disease. Isogenic controls made using 
human specimen can model human lesions with greater specificity to human physiology than animal 
models can (Shi, Inoue, Wu & Yamanaka, 2017; Ben Jehuda, Shemer & Binah, 2018).  
There are several different approaches to creating clonal cell lines. Clonal cell lines must be uniform 
and identical, originating from a single original cell that has the selected or engineered characteristics. 
To achieve this, after genome editing or selection, a cell population must be isolated into single cells. 
A common method for many cell types is cell sorting (FACS) and subsequent expansion sorted cells 
into clonal cell lines (Ran et al., 2013). In FACS, a heterogeneous cell population is sorted one cell at 
a time based on the fluorescent characteristics and specific light scattering of each cell. Cells with 
certain target characteristics, such as genome-edited cells containing a fluorescent label tagging the 
target region can be separated from those cells that do not have the characteristic by FACS (Bonner et 
al., 1972; Ran et al., 2013; Haupt et al., 2018). Immunomagnetic separation and microfluidic cell 
sorting are other precise methods for cell separation (Rahmanian et al., 2016).  For the purpose of in 
vitro disease modelling with clonal cell lines, cell populations can also be separated into single cells 
by manual colony picking. An advantage of this cell sorting approach over FACS is the higher 
survival rate of electroporated iPSC (Bruntraeger et al., 2019). 
 1.7 CRISPR-Cas  
1.7.1 Origins of CRISPR-Cas and developments in research 
The discovery of clustered DNA repeats in prokaryotes occurred around the same time in three 
different parts of the world (Hermans et al., 1991; Ishino et al., 1987; Nakata et al., 1989). A 1987 
study investigating the role of isozyme conversion of alkaline phosphatase in Escherichia coli, which 
sequenced a DNA fragment spanning the region of iap gene (isozyme of alkaline phosphatase), was 
the first study to recognise short DNA repeats in prokaryotes (Ishino et al., 1987). In 1993, similar 
DNA repeats were observed in the archaea Haloferax mediterranei, and since then in nearly all of 
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archaeal and about half of bacterial genomes (Ishino et al., 2018).  Across the 1990s and early 2000s, 
Francisco Mojica’s work further demonstrated that the spacer regions of the DNA repeats were 
similar to bacteriophages (Mojica et al., 1993; Mojica et al., 2005).  
In 2001, the term CRISPR for Clustered Regularly Interspaced Palindromic Repeats was conjoined to 
refer to the DNA-repeats found in archaea and bacteria. Four conserved genes that are found adjacent 
to CRISPR regions were designated as cas genes (CRISPR-associated genes) 1-4. The CRISPR locus 
consists of three components, which are cas genes, a leader sequence, and a repeat-spacer array. In 
2005, Bolotin’s studies of Streptococcus thermophilus discovered that the CRISPR array contained 
novel cas genes, including a large cas gene with nuclease activity that later became known as Cas9. 
The study also revealed that the spacers that have homology to viral genes all shared a common 
sequence at the end, the PAM (protospacer adjacent motif) sequence (Bolotin et al., 2005).  
The role of CRISPR-Cas in bacterial immunity for defence against viruses gathered more evidence in 
2006 (Makarova et al., 2006). CRISPRs consist of DNA sequence repeats, and spacer sequences, 
which are remnants of foreign DNA of viruses that have previously invaded. In 2008, it was 
demonstrated that spacer sequences derived from phages or plasmid DNA are transcribed into 
CRISPR RNAs (crRNAs), which are small RNAs that guide Cas proteins to the target and interfere 
with the foreign genome (Brouns et al., 2008). The crRNA interferes with DNA also, not only RNA 
as previously hypothesised based on the view that CRISPR is parallel to RNAi interference in 
eukaryotes (Maraffini & Sontheimer, 2008). Garneau et al. (2010) demonstrated the distinguishing 
feature of Type II CRISPR systems at work, which is that double-strand breaks can be created three 
nucleotides upstream of the PAM mediated by Cas9 in conjunction with crRNA. In 2011, small RNA 
sequencing of Streptococcus pyogenes found that the CRISPR-Cas9 system contains another small 
RNA, trans-activating CRISPR RNA (tracrRNA), that forms a duplex with crRNA and guides Cas9 to 
the target location (Deltcheva et al., 2011). In 2013, the Zhang lab published the first CRISPR-Cas 
method to edit mouse and human genomes (Cong et al., 2013).  
1.7.2 The CRISPR-Cas immunity mechanism and types of CRISPR-Cas 
The CRISPR-Cas adaptive immunity system can be divided into three phases by which it recognises 
and cleaves foreign DNA or RNA: (i) Adaptation, (ii) crRNA biogenesis, and (iii) Target interference 
(Figure 4a). In the adaptation phase, a prokaryote comes into contact with an invading Mobile Genetic 
Element, from which a protospacer sequence is incorporated into the CRISPR array (collection of 
identical repeat sequences) as a new spacer. In the crRNA biogenesis phase, immunity is enabled 
when the CRISPR array is transcribed into a long precursor crRNA (pre-crRNA), which is further 
processed by Cas proteins into a mature crRNA containing the sequences of invaders. In the target 
interference phase, mature crRNAs activate the CRISPR mechanism and act as guides to target and 
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interfere with the cognate invading DNA or RNA, and the Cas protein cleaves them (Hille & 
Charpentier, 2016).  
CRISPR-Cas systems can be divided into two main classes, which involve six types and several more 
subtypes, based on Cas genes, operons, and CRISPR loci (Barrangou, 2015). Class 1 CRISPR-Cas 
systems (types I, III and IV) have an effector Cas protein module consisting of a multi-protein 
complex. Class 2 systems (types II, V and VI) use only one effector protein for target interference. To 
avoid self-targeting, types I and V recognise the PAM sequence that is located upstream of the 
protospacer, and type II recognises the PAM downstream of the protospacer (Ishino et al., 2018; Hille 
& Charpentier, 2016). Type I consists of multiple Cas proteins, forming a chain with the Cas3 protein. 
Type II involves its characteristic protein Cas9. Cas1 and Cas2 are involved in adaptation in both 
main CRISPR-Cas types (Ishino et al., 2018).  
Type II CRISPR-Cas systems, or CRISPR-Cas9, are characterised by the CRISPR-repeat spacer 
array, a Cas9 gene as the first gene in an operon containing two to three cas adaptation modules 
(Cas1, Cas2, csn2, or Cas4), along with a tracrRNA (Charpentier et al., 2015). Cas9 has six domains, 
REC I, REC II, Bridge Helix, PAM-interacting (PID), and HNH and RuvC (Jinek et al., 2012). The 
PID recognises the PAM sequence in the invading genome. REC I is involved in binding the guide 
RNA to the target DNA. The PID binds to PAM, and initiates binding to target DNA. A defining 
feature of the type II (and type I) systems is the R-loop, which forms when the guide RNA segment of 
a crRNA invades a DNA double helix to form an RNA-DNA hybrid helix with the target DNA strand 
while displacing the non-target strand (Figure 4b) (Jinek et al., 2012). In CRISPR-Cas9, the Cas9 
endonuclease together with a crRNA and a tracrRNA can form an R-loop (Jiang et al., 2016). The R-
loop interaction occurs on the target strand by complementary pairing with the guide RNA, with a 
double-stranded DNA cleavage by Cas9 3 bp upstream of the PAM. The double strand cleavage 
occurs via the HNH and RuvC catalytic sites (Anders et al., 2014). In Streptococcus pyogenes, the 











              
B. 
                             
Figure 4. The CRISPR-Cas9 system. (A) CRISPR-Cas9 mediated DNA interference in bacterial 
adaptive immunity. The CRISPR-Cas adaptive immunity mechanism is usually described in three 
20 
 
steps: First in adaptation, a new spacer (dark green) from invading phage DNA is incorporated into 
the CRISPR array by acquisition machinery (Cas1, Cas2, Csn). The tracrRNA precedes the Cas 
operon, and encodes unique non-coding RNA homologous to the repeat sequences. After integration, 
the new spacer is transcribed together with all other spacers into a long precursor-crRNA (pre-
crRNA) containing repeats (brown lines) and spacers  (dark green, blue, light green, yellow lines). In 
crRNA biogenesis, the tracrRNA anneals to the pre-crRNA repeats for crRNA maturation by RNase 
III cleavage. The length of the crRNA is reduced to ~20 nt by trimming at the 5’ end (grey arrows). 
During DNA interference, the crRNA-tracrRNA structure directs the Cas9 endonuclease to cleave the 
foreign DNA that contains the 20 nt crRNA complementary sequence preceding the PAM site (Image 
from Jiang & Doudna, 2017). (B) Target DNA binding and cleavage by the Cas9 endonuclease. (1) 
The crRNA-tracrRNA guided Cas9 scans the DNA for a suitable PAM. (2) When the crRNA 
sequence binds to the target DNA, (3) the RuvC and HNH domains of Cas9 cleave the DNA 3 bp 
upstream of the PAM (Image from Jinek et al., 2014). 
1.7.3 CRISPR-Cas9 in genome editing and disease modelling 
Genome editing (or gene editing) refers to the technologies used to target and add, remove, or alter 
parts of an organism’s DNA (Fernandez et al., 2017). CRISPR-Cas9 has been found to be the most 
efficient and customisable for editing multiple genes at once and in a range of eukaryotic cells, 
compared to other previously developed genome editing methods. Different genome editing 
applications including CRISPR-Cas9 are used increasingly widely in disease modelling in cell-based 
and whole animal-based systems (Paquet et al., 2016; Jin et al., 2019; Platt et al., 2013). Genetic loci 
can be knocked-out or modified, or transcription regulated, to investigate their function in a particular 
biological pathway and phenotype (Hille & Charpentier, 2016; Paquet et al., 2016). CRISPR-Cas9 
systems are also being researched as diagnostic tools for the diseases being modelled, antimicrobial 
treatments, and as autologous transplantation treatment for degenerative disorders, to target the 
genome and epigenome of cells in cancers (Martinez-Lage et al., 2018), and to repair mutations ex-
vivo in somatic and induced pluripotent stem cells for the treatment of monogenic disorders (reviewed 
in Savic &Schwank, 2016). In 2020, the Nobel prize in Chemistry was awarded to Jennifer Doudna 
and Emmanuelle Charpentier for the development of the CRISPR-Cas9 method for genome editing.  
Genome editing methods used for disease modelling and therapy research prior to CRISPR-Cas9 
include zinc-finger nucleases (ZFN) and transcription activator-like effector nucleases (TALEN). 
Beginning from early 2000s, ZFN were the first generation of genome editing tools applied to gene 
correction, addition and disruption in plant and mammalian cells including mouse and human 
pluripotent stem cells (Urnov et al., 2010). The ZFN structure consists of a zinc finger protein (ZFP) 
array of 3-6 Cys2-His2 zinc-finger domains fused in tandem, with each domain binding to 3 
nucleotides, and a Fok1 endonuclease domain fused with an intervening linker to the ZFP (Kim et al., 
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1996). TALENs also work through a FokI endonuclease fused to a DNA binding domain derived 
from TALE proteins originally found in Xanthomonas sp. Each domain interacts with a single target 
nucleotide and allows genome editing in any location in the genome through the nuclease creating a 
DSB that gets corrected through NHEJ. However, the Fok1 endonuclease works in a dimer and is 
cumbersome to design to target a very specific region (binds 3 nucleotides in ZFN) and to transfect to 
some cell types (Boch et al., 2009). Although ZFN and especially TALEN setups have been improved 
for life science and disease modelling , the advantage of CRISPR-Cas9 over other genome editing 
methods is its efficiency due to the robustness and relatively small size of the Cas9 endonuclease, 
speed of assembly, customisability and affordability of guide RNAs for a range of mammalian cells, 
especially difficult to transfect cells such as iPSC (Ding et al., 2013; Ran et al., 2013, Hockemeyer & 
Jaenisch, 2017; Giacalone et al., 2018).  
CRISPR-Cas is used as a genome editing technology repurposed and adapted from the naturally 
occurring genome editing system that archaea and bacteria use for adaptive immunity. CRISPR-Cas9 
genome editing harnesses the use of a synthetic sgRNA, usually consisting of a crRNA and tracrRNA 
in a duplex, and Cas9 endonuclease. sgRNAs are non-coding RNA sequences with helicase- and 
nuclease active components, that target the complementary target DNA locus. Allele-specific and 
non-allele specific sgRNAs can be synthesised by polymerase chain reaction (PCR) (Balboa et al., 
2015), or be cloned into plasmids that are transfected into cells. The PCR-synthesised sgRNA 
transcriptional cassette consists of a U6-promoter that controls sgRNA expression in transfected cells, 
and crRNA-tracrRNA complex consisting of a 20 bp gRNA and a 19 bp matching tracrRNA (Balboa 
et al., 2015).  
There are two main pathways by which DSBs are repaired: non-homologous end joining (NHEJ) and 
homology directed repair (HDR). NHEJ occurs more commonly in eukaryotic cells when repairing a 
DSB created by a Cas endonuclease. NHEJ usually results in insertions/deletions (INDELs), which 
can result in frameshifts or premature stop codons, preferable for making knockout mutations (Hille & 
Charpentier, 2016). HDR, the most common form being homologous recombination, can be harnessed 
to repair mutations or insert precise mutations with a homologous DNA sequence (Lieber, 2010). The 
homologous duplex template can be naturally occurring, or synthetic to create large modifications, 
such as a knock-in mutation, or to insert reporter genes (Ran et al., 2013; Cong et al., 2013). HDR 
usually only occurs in the G2/S cell cycle phase, while NHEJ is not dependent on cell cycle phase 
(Heyer et al., 2010). DSB repair through the HDR pathway also depends on cell type, the design of 
the repair template, and target location in the genome (Saleh-Gohari, 2004; Ran et al., 2013).  
One method to deliver CRISPR-Cas components, including CRISPR-Cas9, into cells in vitro is by 
using a ribonucleoprotein (RNP) complex (Lin et al., 2014). An RNP complex consists of a targeting 
sgRNA in complex with a Cas9 protein. The sgRNA consists of a unique short ~20 nucleotide target-
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specific CRISPR-RNA (crRNA) that corresponds to the target genomic DNA region on either strand, 
and a trans-activating RNA (tracrRNA) that is the stem-loop structure bound by the Cas9 nuclease 
(Figure 5). The genomic DNA region corresponding to the crRNA must be chosen so that the 3’ end 
has a protospacer adjacent motif (PAM) sequence (5’-NGG-3’, where N is any nucleotide base), 
which is a 2-6 nucleotide sequence downstream of the DNA sequence targeted by the crRNA. The 
crRNA-tracrRNA duplex directs the Cas9 protein to a site upstream of the PAM sequence, and Cas9, 
activated by binding of the crRNA, makes a DSB 3-4 bp upstream of the PAM (Jinek et al., 2014). In 
addition to the RNP complex, a repair template can be added in a plasmid, PCR-product or chemically 
synthesised oligonucleotide to insert a new sequence with any wanted mutation. Repair templates can 
be single- (single-stranded donor oligonucleotide, ssODN) or double stranded (double stranded DNA, 
dsDNA). An ssODN, recommended for single-nucleotide substitutions used in this project, is a 101-
nucleotide long strand containing homology arms of ideally 75-100 nt (in this project 50 nt) 
corresponding to the sequence immediately flanking the mutation site at 5’ and 3’ ends. An ssODN 
can either be complementary to the 5’-3’ or 3’-5’ strand (Ran et al., 2013). Major advantages of 
ssODN over dsDNA templates are their lower toxicity and lower frequency of random integration (Li 






                      
Figure 5. Schematic of the CRISPR-Cas9 ribonucleoprotein (RNP) system for gene editing 
through the NHEJ and HDR pathways. The crRNA contains a unique 20 nt sequence 
complementary to the target sequence in the genome. The crRNA-tracrRNA duplex guides the Cas9 
endonuclease to the target region to create a double-strand break 3-4 nucleotides upstream of the 
PAM, resulting in a DSB. A DSB can be repaired by NHEJ to make insertions, deletions or 
substitutions, or through HDR with a homologous repair template to make a precise desired 
modification (Figure adapted from Jiang & Doudna, 2017).  
Electroporation is the most common and efficient RNP nucleofection method to date for introducing 
substrates into the cytoplasm and nucleus of a cell, especially for difficult to transfect cells like iPSC 
(Ihry et al., 2018). Electroporation creates pores in the lipid bilayer of the cell membrane, increasing 
permeability for the RNP complex to enter the cytoplasm. Since the RNP complex degrades relatively 
quickly and acts on the cells only for 24 hours post-electroporation, so mosaicism and off-target 
cleavage and mutagenesis by the spCas9 protein can be minimised (Kim et al., 2014; Bruntraeger et 
al., 2019). In addition to cutting at the site targeted by the crRNA, Cas9 can cut imperfectly matched 
sequences elsewhere in the genome, called “off-target” insertions and deletions (Fu et al., 2013). Off-
targets can be reduced by designing truncated <20 nt gRNAs with low similarity to sequences 
elsewhere in the genome (Fu et al., 2014). The PAM sequence should be as close as possible to the 
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mutation and not be present elsewhere in the genome in high quantities. An ssODN as close as 
possible to the DSB site is most efficient for making single-nucleotide changes (Bruntraeger et al., 
2019). To maximise chances of HDR-pathway exploitation by the ssODN, HDR enhancing small 
molecules can be added into transfected cell populations. HDR enhancers work by inhibiting NHEJ 
(e.g. with DNA-PKc inhibitors and other inhibitors for enzymes involved in DSB processing) 
(Shrivastav et al., 2008), or by enhancing HDR, by compounds arresting cells in G2/S phase when 
HDR is more likely to occur. Naturally, cells in the proliferative phase are more favourable to HDR 
(Heyer et al., 2010).  
1.8 Aims 
The overarching aim of this project was to create the patient mutation c.1347 G>A in SARS2 into an 
established healthy iPSC line. The edited iPSC lines are then applicable for differentiation into the 
affected cell type for further discovery of disease mechanisms.  
The more specific aims were:   
1. To create iPSC lines using CRISPR-Cas9 genome editing for disease modelling of a patient-
specific SARS2 splicing variant c.1347 G>A that causes severe childhood-onset progressive spastic 
paresis.  
2. To analyse the efficiency and precision of the genome-editing and quality of the genome-edited 
iPSC lines, and thereby validity of the models to be used in studies of disease mechanisms.  
3. To analyse the effect of the SARS2 splicing variant c.1347 G>A on mRNA expression and protein 




2. Materials & Methods 
2.1 Cell culture  
2.1.1 HEK293 cells 
HEK293 cells were cultured on a 100 mm cell culture dish (Thermo Scientific, #130182) in DMEM 
(Lonza, #BE12-614F)- based cell culture medium containing 10% Foetal Bovine Serum (FBS) 
(Merck, #TMS-013-B), 1% penicillin-streptomycin (Lonza, #09-757F), and 1% L-Glutamine 
(Thermo Scientific, #25030149). Cells were passaged using 1x Trypsin (Thermo Scientific, 
#R001100) and stored in an incubator at conditions +37 °C, 5 % CO2 and 95 % O2. 
2.1.2 iPSC 
Human iPSC line HEL24.3 was previously reprogrammed from a healthy control’s neonatal foreskin 
fibroblasts by Sendai virus technology (Trokovic, Weltner & Otonkoski, 2015) at Biomedicum Stem 
Cell Center (University of Helsinki, Finland). SARS2 patient cell line HEL204.6 was reprogrammed 
from the patient’s skin fibroblasts into pluripotent stem cells also at the Biomedicum Stem Cell 
Center.  
The patient and control iPSC (for use as healthy control and as parental for CRISPR-Cas9 
electroporation) were cultured on 10 µg/mL Vitronectin XF (STEMCELL Technologies, #07180) in 
PBS (Lonza, #17-516F) coated 35 mm cell culture plates (Thermo Scientific). Cell culture medium 
was TeSR™-E8™ basal medium (#05990) supplemented with TeSR™-E8™ supplement 
(STEMCELL Technologies) and 1:500 Primocin antibiotic (Invivogen, #ant-pm-05). Post-thawing 
and pre- and post-electroporation, the cell culture medium was also supplemented with 1:100 
RevitaCell Supplement (Thermo Scientific, #A2644501) that contains p160-Rho-associated coiled-
coil kinase (ROCK)-inhibitor for 24 hours to regulate apoptosis and aid cell survival. Cells were 
passaged to multiple dishes upon reaching 80-90% confluency, using 1 mL of Gentle Cell 
Dissociation Reagent (STEMCELL Technologies, #07190) per 35 mm dish. iPSC were stored in an 
incubator at conditions +37 °C, 5 % CO2 and 95 % O2.  
2.1.3    Fibroblasts 
Fibroblasts were cultured on a 100 mm cell culture dish (Thermo Scientific, #130182), in DMEM 
(Lonza)- based cell culture medium containing 10% Foetal Bovine Serum (FBS) (Merck, #TMS-013-
B), 1% penicillin-streptomycin (Lonza, #09-757F), 1% L-Glutamine (Thermo Scientific, #25030149), 





2.2 crRNA design  
Four crRNAs to target SARS2 exon 14 in iPSC were designed using the web tools 
https://benchling.com/crispr and https:/crispr.mit.edu based on the SARS2 gene Ensembl gene 
ENSG00000104835, location Chromosome 19: 38,915,266-38,930,763 (GRCh38.p13, Homo 
sapiens), between positions 33769-33849. The crRNAs were 20 nt long, with SpCas9 PAM NGG. 
crRNA1 and crRNA2 were designed to target the forward genomic strand and crRNA3 and crRNA4 
targeted the reverse genomic strand. Cut distances as close as possible to the c.1347 G>A mutation 
was 5 nt in crRNA1 (in the PAM region), 0 nt for crRNA 2 and 3, and 1 nt for crRNA 4 (Table 1). 
The crRNAs tested in HEK293 cells are called crRNA 1-4, and of these the two crRNAs (1 and 4) 
chosen for iPSC electroporation are called crRNA 1 and 2 respectively.  
Specificity and efficiency of the crRNAs was simulated by CRISPOR version 4.97 (Concordet & 
Haeussler, 2018; http://crispor.tefor.net/) and Benchling. CRISPOR’s CFD (cutting frequency 
determination) specificity score ranges from 0-100, 100 being most specific associated with fewer off-
target effects. It correlates better with the total off-target cleavage fraction of a guide and has fewer 
false-positive off-targets and is more sensitive to off-targets with a single-mismatch from the guide 
RNA than the MIT-score, which the CFD is modelled after to measure uniqueness of a guide RNA in 
the target reference genome (Tycko et al., 2019). CFD specificity scores were 93 for crRNA1 and 82 
for crRNA2. The specificity of the crRNAs were sufficient enough (CFD of >60) to be chosen for the 
CRISPR-Cas9 editing of iPSC. Benchling provided on-target and off-target scores from 0-100, 100 
being better. On-target scores represent the probability of Cas9 binding to the region targeted by the 
crRNA. The off-target score is the inverse probability of off-target binding by Cas9 endonuclease, so 
a higher score indicates a lower chance of Cas9 binding elsewhere in the genome (Doench et al., 
2016). crRNA oligonucleotides were supplied by Integrated DNA Technologies (IDT) (Table 1).  
crRNA Sequence 
(5’ → 3’) 





























Reverse ggg         1 82 49.7/45.6 
Table 1. Characteristics of the crRNA sequences designed to target SARS2 exon 14 
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2.3 gRNA production 
Transcriptional units for gRNA expression were prepared by PCR-amplification and concatenated 
using Golden Gate assembly as described in Balboa et al., 2015. The PCR-amplification generated 
short products that include the 5’ tailed U6 promoter, the gRNA sequence, and the tailed terminator. 
Four SARS2 non-allele specific gRNA sequences were produced (Table 4). All PCR amplifications 
were done using the Bio-Rad S1000TM Thermal Cycler.  
The 5’ tailed U6 promoter was generated by digesting plasmid PX335-dCas9-VP192-PGK puro (gift 
from Timo Otonkoski) with restriction enzymes Bbsl and Pvul (Thermo Scientific, #ER1011 and 
#ER0621). 5 ng of the product was run on a 1% w/v agarose gel (in TBE) for 1 hour, and the 1500 bp 
band cut from the gel under UV light and purified using the Nucleospin Tissue XS kit (Macherey-
Nagel # 740901.50). 20 ng of the purified U6 template was used for a PCR reaction, along with 4 µL 
5X HF buffer, 1.6 µL of 2.5 mM dNTP's, 1 µL each of both forward and reverse primers, 0.2 µL 
Phusion enzyme (Thermo Scientific # F530S), filled up to 20 µL with nuclease-free H2O (Table 2). 
The PCR product was purified using the PCR and Gel Cleanup kit (Macherey Nagel #740609.50) and 
digested with Bbsl overnight to eliminate any remaining plasmid. The product was run on a 1% 
agarose gel, and the the 266 bp band cut from the gel under UV light and purified through the 
Nucleospin Tissue XS kit (Macherey Nagel). SYBR® Safe DNA gel stain was used as the nucleic 
acid visualisation stain in the agarose gel (Thermo Scientific, #S33102).  
Number of Cycles Temperature (˚C) Time   
1 x 98 3 min 






1 x 72 8 min 
Table 2. PCR for U6-promoter  
The previously digested U6 promoter (20 ng) and tailed terminator were then PCR amplified 
separately. For the PCR reactions of both products, 20 µL of HF buffer, 8 µL of 2.5 mM dNTPs, 0.5 
µL of 100 µM Forward and Reverse primers, 1 µL of Phusion enzyme (Thermo Scientific), and 2 µL 
of U6 or TT template, and filled up to 100 µL with MilliQ water (Table 3). The PCR products were 
loaded on 1% agarose gel (BioNordika, #BN-50004) in TBE, with negative water controls included, 
266 bp U6 band and 103 bp tailed terminator band were cut under UV light and purified using the 
PCR and Gel Cleanup kit (Macherey Nagel).  
The final gRNA expression cassette including the U6 promoter and tailed terminator was assembled 
by a PCR reaction containing 5 ng of both the U6 promoter and tailed terminator, 20 µL 5x HF-
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buffer, 8 µL 2.5 mM dNTPs, 2 µL 1 µM gRNA, 0.5 µL of 100 µM both Forward and Reverse 
primers, 1 µL Phusion enzyme (Thermo Scientific), and filled to 20 µL with nuclease-free H2O and 
run with the cycling program (Table 2). 5 µL of the PCR products were loaded on a 1% agarose gel in 
TBE and checked for a 455 bp band. The rest of the PCR product was then purified using the PCR 
and Gel Cleanup kit (Macherey-Nagel).  
Number of Cycles Temperature (˚C) Time 
1 x 98 3 min 




30 s  
12 s  
1 x 72 8 min  









































































Table 4. Sequences in non-allele specific sgRNA PCR-product synthesis. The underlined portion is 
the gRNA.  
2.4 gRNA testing in HEK293 cells  
The four assembled and concatenated gRNA sequences were transfected into HEK293 cells to 
determine transfection efficiency. A 48-well plate of 90% confluent HEK293 cells was chosen for the 
jetPRIME (Polyplus) protocol. Three transfections were done for each gRNA, and alongside a GFP-
Cas9 only control and a negative control without the jetPRIME reagent.  
0.1 µg of sgRNA, 50 µL of jetPRIME buffer, 0.5 µg of GFP-Cas9-Plasmid were mixed and vortexed. 
1 µL of jetPRIME reagent was added, vortexed for 10 seconds, spun down, and incubated at room 
temperature for 20 minutes. 50 µL of the transfection mix was added per well of the 48-well plate. 
The plate was rocked gently side to side and placed in an incubator in conditions +37 °C, 5 % CO2 
and 95 % O2. The transfection medium was replaced with TeSR-E8 medium after 4 hours and 
returned to the incubator.  
After 48 hours, GFP-positivity was checked on the EVOS® F fluorescence microscope (Life 
Technologies) for an estimate of transfection efficiency. Cells were collected by first washing with 
400 µL PBS (Lonza) and adding 400 µL 1x Trypsin-EDTA in PBS, incubating at 37 °C for 3 minutes. 
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Cells were collected into 1 mL DMEM/F-12 (Gibco #11320033), centrifuged at 200 g for 3 minutes, 
supernatant aspirated, and pellet stored at -80 °C.  
2.5 T7 endonuclease assay 
The T7 assay (NE Biolabs #M0302S) is based on the formation of homo- and heteroduplexes between 
PCR-amplified genomic wild type and mutant DNA fragments. Mutant, in this case edited DNA, 
contain mismatches that are cleaved by the T7 enzyme and can be visualised on an agarose gel. A 
cleaved T7-result suggests sufficient activity of the non-allele specific gRNA, or gRNA at the target 
site.  
Genomic DNA was first extracted by adding 15 µL QuickExtract DNA Extraction Solution (Lucigen 
#QE09050) into approximately 104 cells from a 96-well plate well, vortexing for 15 seconds and 
incubating at 65 ˚C for 6 minutes, vortexing for 15 seconds and incubating at 98 ˚C for 2 minutes. 
Genomic DNA extraction from cells expanded on 48-well and 35 mm cell culture plates was done 
according to instructions from the NucleoSpin Tissue Mini Kit (Macherey Nagel, #740952.50). PCR-
amplification was set up with 12.5 µL of AmpliTaq Gold 360 Master Mix (Thermo Scientific # 
4398881), 0.5 µL of 10 µm forward and reverse primers, 100 µg DNA template filled to a 25 µL 
reaction with nuclease-free H2O (Table 5). The AmpliTaq Gold positive kit control (Thermo 
Scientific, #N8080241) was run in parallel. 5 µL of the PCR-amplified product was run on a 3% 
agarose gel at 110V for 1 h 30 min to detect a single band of correct size at 206 bp.  
Number of Cycles Temperature (˚C)  Time  
1 x 95 10 min 






1 x 72 7 min 
1 x 4 Hold 
Table 5. T7-assay thermocycling program 
To proceed with the cleavage assay, heteroduplex formation was set up with 10 µL PCR-product, 2 
µL NE-Buffer (NE Biolabs), filled to a 19.5 µL reaction with nuclease-free H2O. Negative enzyme 
controls were run in parallel. The samples were denatured and annealed by thermal cycling at 95 °C 




Number of Cycles Temperature (˚C) Time 




Table 6: T7-assay denature and anneal thermocycling program 
The annealed products are digested with the T7 endonuclease I. 1 µL of T7 endonuclease (NE 
Biolabs), or H2O for negative enzyme controls, was added to the 19.5 µL of the annealed product. The 
samples were resuspended and incubated at 37 ˚C for 15 minutes and inactivated with 1 µL 0.5 M 
EDTA (Thermo Scientific #15575020). The samples were analysed on 2% agarose gel at 100 V for 1 
h 30 min. Imaging was done with Bio-Rad ChemiDoc XRS+, and band intensity and percentage of 
DNA cleaved was quantified using ImageLab 6.0.  
Gene modification efficiency f (percentage of DNA cleaved in the pool of cells) was calculated with 
the following equation: 
 𝑓 = 100𝑥 [1 − (1 − 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑐𝑙𝑒𝑎𝑣𝑒𝑑)
1
2], where the fraction cleaved is the sum of cleaved bands. 
2.6 ssODN repair template design  
Two repair templates to be used in conjunction with the two crRNAs to create the knock-in mutation 
c.1347 G>A were designed to be 101 nucleotides long (Benchling, https://benchling.com/crispr). 
Guanine was changed to adenine, and 50 nucleotides of the wild type DNA was added to both sides of 
the mutation site as homology arms. The patient mutation is in the last nucleotide of exon 14, so the 
ssODN contains 15 nucleotides of intron. In ssODN 2, one guanine in the PAM-sequence (NGG) was 
changed to another nucleotide to become NCG, to avoid the ssODN sequence being cleaved by Cas9 
before or after HDR. ssODN 1 was designed to be in sense orientation since crRNA 1 was in forward 
orientation, and ssODN 2 designed to be antisense since crRNA 2 was reverse. A silent mutation and 
restriction site were not designed in order to avoid additional and possibly deleterious mutations in the 




ssODN Sequence Orientation 
ssoDN 
1 
5’-CTC CAC ATC ATG TTC CAG ACC GAG GCT GGG 
GAG CTG CAG TTT GCC CAC ACA GTG AGG CCC 
GCA CAG CCT CCT GCC CGC GTG CCC TCG CCC 




5’-GCA GAG GCT GCG GGC GAG GGC ACG CGG 
GCA GGA GGC TGT GCG GGC CTC ACT GTG TGA 
GCA AAC TGC AGC TCC CCA GCC TCG GTC TGG 
AAC ATG ATG TGG AG-3’ 
Antisense 
Table 7. ssODN repair template sequences used in iPSC CRISPR-Cas9 RNP complex 
electroporations. ssODN 1 is used in conjunction with crRNA 1 and ssODN 2 with crRNA 2. The 
knock-in mutations are indicated in bold.  
2.7 Creating the genome edited iPSC lines 
2.7.1 Electroporation 
Cells were passaged with 0.75X TrypLESelect cell dissociation enzyme (Thermo Scientific 
#12563029) in PBS (Lonza) two days before electroporation to accustom the proliferative cells to a 
single-cell state. Confluence on the day of electroporation was 70% in four 35mm cell culture plates 
(Thermo Scientific). This translates to about two million cells per electroporation as counted by 
Countess Automated Cell Counter (Thermo Scientific). Three hours before electroporation, fresh cell 
culture medium containing RevitaCell supplement was added to enhance survival throughout the 
process.  
First, the AltR® CRISPR-Cas9 crRNA and 20 nmol Alt-R® CRISPR-Cas9 tracrRNA, ATTO™ 550 
(IDT, #1075925) were individually resuspended in a nuclease-free buffer (IDT) to a final 
concentration of 200 µM in a dark Eppendorf tube. The crRNA/tracrRNA duplex was formed by 
resuspending the crRNA and tracrRNA together to a final concentration of 100 µM, incubated at 95 
°C for 5 minutes and allowed to cool down to room temperature. Second, the ribonucleoprotein 
(RNP) complex was formed by combining in a 1.5 mL Eppendorf tube 3 µL of the crRNA/tracrRNA 
duplex, 3 µL of 10 µG recombinant Alt-R® S.p. HiFi Cas9 Nuclease V3 (IDT, #1081061), 2 µg 
ssODN (IDT), and 3 µL of Neon electroporation R buffer (Invitrogen, #MPK10096). The complex 
was incubated at room temperature for 20 minutes.   
iPSC were washed once with 1 mL 5% FBS-PBS and dissociated using 1 mL 0.75X TrypLE Select 
(Thermo Scientific) at 37 °C for 3 minutes. Cells were pipetted carefully into a 50 mL polystyrene 
Falcon tube containing 4 mL 5% FBS-PBS and centrifuged at 250 g for 5 minutes. The pellet was 
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resuspended into 1 mL 5% FBS-PBS. The number of live cells was counted with Countess Automated 
Cell Counter (Thermo Scientific), and two million cells were taken into a 1.5 mL Eppendorf tube, 
centrifuged at 200 g for 3 minutes and resuspended in 300 µL Neon electroporation R buffer 
(Invitrogen). Then, 9 µL RNP complex, 6 µL electroporation enhancer (IDT, #1075915), 6 µL ssODN 
and 6 µL pCXLE-mp53DD plasmid (AddGene, #41859) were mixed with the cells. With the Neon 
pipette, 100 µL of the mixture was taken into in a cuvette with 3mL electroporation buffer E2 
(Invitrogen) and electroporated with two pulses of 1100V for 20 ms with the Neon Electroporator 
(Invitrogen).  
Electroporated samples were plated immediately onto pre-warmed 35 mm cell culture plates as 
described earlier, one supplemented with Alt-R HDR enhancer (IDT, #1075915), one with 20 µM, 
and one without HDR Enhancer. Cell culture medium was replaced 24 hours from the electroporation 
and imaged with a fluorescence microscope for the presence of ATTO™ 550 labelled cells to 
determine transfection efficiency in attached cells. Each pool showing a positive fluorescence result 
was passaged 1:3, one for T7 assay and sequencing, one for subcloning, and one for cryopreservation 
as backup. For freezing the electroporated pools, cells were detached and resuspended in 1 mL of 
freezing medium containing DMEM/F-12 (Gibco) with 20% FBS (Gibco, #10270106) and 10% 
DMSO (Merck, #102952). They were incubated at -80 °C overnight and transferred to -140 °C for 
long-term storage.  
2.7.2 Subcloning 
Electroporated iPSC pools were expanded to 80% confluency before subcloning. Cell culture medium 
was aspirated, washed once with 1 mL PBS (Lonza), 1 mL of Accutase (Thermo Scientific) was 
added to each dish, and incubated at +37 °C for 6 minutes to dissociate cells. Cells were collected into 
a 50 mL Falcon tube containing 4 mL TeSR™-E8™ media supplemented with 1X CloneR 
(STEMCELL Technologies, #05888), centrifuged at 200 g for 5 minutes, and resuspended in 1 mL 
TeSR™-E8™ media supplemented with 1X CloneR. The number of live cells was counted with 
Countess Automated Cell Counter (Thermo Scientific), and the volume of triturated medium 
containing 500-1000 cells were plated into 10 cm tissue-culture dishes coated with Vitronectin XF at 
a concentration of 5 µg/cm2 containing 10 mL with TeSR™-E8™ media supplemented with 1X 
CloneR. Dishes were gently rocked to disperse cells evenly and placed in an incubator undisturbed for 
48 hours (Bruntraeger et al., 2019). 
48 hours after subcloning, cell culture medium was replaced with 10 mL of Essential 8 Flex medium 
supplemented with E8 Flex medium supplement (Gibco, #A2858501) and changed every 48 hours for 




2.7.3 Colony picking 
Single-cell derived iPSC colonies of approximately 1-2 mm diameter, uniform morphology and clear 
edges (indicative of colonies originating from one cell) were manually picked from the cell culture 
dish 8 days after low-density seeding of the cells in subcloning. First, medium was aspirated, the dish 
washed once with 5 mL PBS (Lonza), and 5 mL Gentle Cell Dissociation Reagent (STEMCELL 
Technologies, #07174) added and incubated at 37 °C for 2 min 30 s. Dissociation reagent was 
aspirated carefully without disturbing the colonies, and 10 mL of TeSR™-E8™ medium added. Using 
a dissection microscope, individual colonies were scraped and collected in a P20 pipette set at 10 µL 
and transferred into a U-bottom 96-well plate (Corning, #0058) containing 100 µL TeSR™-E8™ 
media supplemented with RevitaCell Supplement (Thermo Scientific) per well. A fresh tip was used 
for each colony to prevent cross-contamination. Cells were triturated 6 times and 50 µL transferred to 
one 96-well cell culture plate (Thermo Scientific) coated with Matrigel (Corning), and 50 µL to 
another 96-well cell culture plate coated with Vitronectin XF (STEMCELL Technologies) to create 
duplicate plates of colonies.  
2.7.4 Cryopreservation of clonal cell lines 
Five days post-picking at 60-90% confluency, the colonies from the Matrigel-coated plates were 
passaged 1:2 into two Matrigel-coated 96-well plates (Thermo Scientific). Once 60-90% confluent, 
spent medium was removed, colonies washed once with 100 µL PBS (Lonza), 25 µL of pre-warmed 
Accutase (Life Technologies) added per well and incubated at 37°C for 6 minutes. 75 µL of Knock-
Out Serum Replacement (Life Technologies, #10828128) was added per well to quench the 
dissociation reaction. The colonies were triturated 6 times, and 100 µL of Knock-Out Serum 
Replacement containing 20% DMSO added. The solution was triturated 4 times, and the contents 
transferred into a 96-well 0.5 mL 2D matrix plate (Thermo Scientific, #3725). 100 µL of sterile 
EmbryoMax® light mineral oil (Millipore, #ES-005-C) was added on top of the freezing medium to 
prevent evaporation. The matrix plates were incubated at -80°C overnight and transferred to liquid 
nitrogen for long term storage.   
2.7.5 Thawing 
Individual vials from the matrix plates were removed from liquid nitrogen and thawed rapidly at room 
temperature. Mineral oil was removed with a pipette, and cells suspended in freeze medium were 
transferred into 1 mL of pre-warmed TeSR-E8 medium and centrifuged at 300 x g for 3 minutes. 
Pellets were resuspended in 400 µL TeSR-E8 medium supplemented with CloneR, transferred into 
individual 48-well plate wells coated with Vitronectin XF at 2 µg/cm2 and cultured overnight at 37°C. 
36 
 
After a 400 µL medium change the following day, cells were expanded to 35 mm cell culture plates 
for secondary genotyping and further analyses.  
2.8 Sanger sequencing 
Primary genotyping of all expanded clonal cell lines was done using the SeqLab sequencing service at 
the Institute for Molecular Medicine Finland (FIMM). The service included product-cleanup, 
sequencing with ABI3730xl DNA Analyzer, and base-calling with Sequencing Analysis 5.2. 
Chromatogram data were interpreted with the Sequencher 5.2.4 software (Gene Codes Corporation), 
and FASTA-file data compared to a reference genome with NCBI BLAST search tool to evaluate 
effects of genome editing.  
First, genomic DNA was PCR-amplified with 12.5 µL of AmpliTaq Gold 360 Master Mix (Thermo 
Scientific), 0.5 µL of 10 µm forward and reverse primers (Table 8), 100 µg DNA template filled to a 
25 µL reaction with nuclease-free H2O (Table 4). The production of a single 206 bp band was 
checked on 2% agarose gel run at 140V for 45 minutes and imaging with Bio-Rad ChemiDoc XRS+. 
The PCR-products were purified for sequencing by adding 2 µL Exo-SAP-IT reagent (Thermo 
Scientific, #78200.200.UL) into 5 µL PCR-product, incubating at 37°C for 15 minutes to activate the 
enzyme, and incubating at 80°C for 15 minutes to inactivate the enzyme. The Ready-To-Run 
sequencing reaction included 5.2 µL MilliQ water, 1.9 µL 5X BigDye dilution buffer (Life 
Technologies, #4336697), 0.25 µL BigDye RR Mix reaction enzyme (Life Technologies), 0.65 µL 5 
µm sequencing primer (Table 9), and 2 µL of purified PCR-product as the template. The samples 
were run in a thermocycler program (Table 8) on Bio-Rad S1000TM Thermal Cycler before delivery to 
FIMM.  
Number of cycles Temperature (°C) Time 
1 x 96 1 min 






 10 Hold until delivery to SeqLab 
Table 8. BigDye 3.1 sequencing protocol thermocycling 
Primer Sequence (5’ → 3’) 
SARS2 exon 14 Forward CCCATCCCTGATCCGCTC 
SARS2 exon 14 Reverse CAAGGTGGGTGGGTCTAGG 




Clone KI 1 from gRNA 2 was TOPO-cloned to determine the sequence of individual strands at the 
mutation due to unclear genotype at the mutation site. First, the high-fidelity PCR reaction was set up 
with 2 µL DNA template, 0.3 µL of 10 µM forward and reverse primers, 5 µL KAPA HiFi HotStart 
ReadyMix (2X) (KapaBiosystems, #KR0370), and filled to 10 µL with nuclease-free H2O. 
Thermocycling was according to the program in Table 10.  
Number of cycles Temperature (°C) Time 
1 x 95 3 min 





30 s  
1 x 72 5 min 
Table 10. KAPA HiFi HotStart ReadyMix PCR cycling program  
The reaction is set up according to the Zero Blunt® TOPO® PCR Cloning Kit instructions (Thermo 
Scientific, #450245). 4 µL of PCR product, 1 µL of salt solution, and 1 µL of pCR™-Blunt-TOPO 
vector were combined. The mixture was incubated for 5 minutes and RT and then transferred to ice.   
The recombinant vector was then transformed into competent E. coli. 2 µL of recombinant vector was 
added to 50 µL of DH5α competent E. coli cells and incubated on ice for 30 minutes. The 
transformation was done with giving the mixture a heat-shock at 42°C for 30 seconds, then 
immediately transferred to ice for 2 minutes. 250 µL of RT S.O.C. medium was added to the mixture 
and incubated horizontally at 37°C for 1 hour on a shaker at 200 rpm. 250 µL of the transformation 
mixture was spread on a prewarmed LB plates containing 50 µg/ml Kanamycin and incubated at 37°C 
overnight. 18 colonies were culture overnight in LB medium containing 50 µg/ml Kanamycin. 
Plasmid DNA for sequencing was isolated using GeneJET Plasmid Miniprep Kit (Thermo Scientific, 
#00827352). 
The Ready-To-Run sequencing reaction for plasmid DNA included 6.35 µL nuclease-free H2O, 1.5 
µL 5X BigDye dilution buffer (Life Technologies), 1 µL 2.5X BigDye RR mix (Life Technologies), 
0.65 µL of 10 µM primer and 0.5 µL plasmid DNA. Thermocycling was according to the program in 




Number of cycles Temperature (°C) Time 
1 x 96 1 min 






 10 Hold until delivery to SeqLab 
Table 11. BigDye 3.1 sequencing protocol thermocycling for plasmid DNA  
2.10 Analysis and sequencing of off-target genome editing 
Off-target genome editing for crRNA 2 was evaluated with CRISPOR Batch Gene Targeting 
Assistant 4.97. The program aligned the crRNA of interest to a reference genome and reported exonic, 
intronic, and intergenic regions with a similar sequence as targeted by the crRNA, and PCR primers 
for these regions. Off-target loci were ranked according to cutting frequency determination (CFD) 
scores. CFD measures the specificity of the crRNA to the target with scores ranging from 0-100 with 
100 suggesting the strongest specificity to the crRNA and 0 suggesting a weak interaction due to 
mismatches between the crRNA and the target. CFD scores are further transformed so that weak 
interactions <20 are reduced to 0 and strong scores >80 are transformed to 100, after which they are 
turned into weighted scores ranging from 0-1. The CFD is based on a large dataset of cleavages in 
cells by infection with a lentiviral library containing thousands of guides targeting the CD33 gene for 
all possible nucleotide mismatches and 1 bp INDELs in all PAMs (Doench et al., 2016; Primers for 
regions with CFD the highest CFD scores, in this case above 0.2 and exonic regions with CFD scores 
above 0.14 were simulated using UCSC in silico PCR (Genome assembly: Dec. 2013 GRCh38/hg38). 
The primers that produced a ~600 bp amplicon at the correct locus were ordered from Merck, and 
regions sequenced using the FIMM service described in section 2.7. Sequences were compared to a 
reference genome using NCBI Basic Local Alignment Tool, Nucleotide Collection. 
2.11 Analyses of HDR efficiency 
The presence of INDELs and efficiency of HDR-mediated knock-ins in the electroporated cell pools 
was done using an online bioinformatics tool ICE CRISPR analysis tool version 2 from Synthego 
(https://ice.synthego.com/#/ , Hsiau et al., 2018). This tool was used to analyse Sanger sequencing 
files of the electroporated cell pools to find INDELs resulting from the use of each of the crRNAs. 
The inputs include the crRNA sequence excluding the PAM, the donor sequence with homology 
arms, and Sanger sequencing files of a reference wild type and the test sample. The output parameters 
are the PAM sequence, INDEL percentage, KO-score, KI-score, model fit (R2). The INDEL 
percentage is the percentage of cells in the pool with a non-wild type sequence, showing overall 
editing efficiency. The KO-score (knockout score) represents the proportion of cells in the sequence 
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that have frameshifts or >21 bp INDEL. The KI-score (knock-in score) is the proportion of cells with 
the desired knock-in mutation. Potential editing outcomes are fitted to observed data by linear 
regression, and model fit shows reliability of the ICE output parameters. Whereas the T7 test 
determined genome editing efficiency by the percentage of INDELs present in electroporated cell 
populations, the ICE CRISPR analysis tool could determine any differences in the rates of HDR and 
INDELs between the two crRNAs used in iPSC electroporation and thereby the efficiencies of the 
differently designed crRNAs. 
2.12 Cell collection for RT-qPCR and Western blotting 
80% confluent iPSC and fibroblasts on 35 mm cell culture dishes were first washed with 1 ml of RT 
PBS to remove cell debris. 1 ml of +4 ºC PBS was added, and cells were detached carefully with a 
cell scraper (Thermo Scientific) and placed on ice. The cell suspensions were centrifuged at 1000 g 
for 10 minutes in +4 ºC, supernatant aspirated, and pellets stored -80 ºC.  
2.13 RT-qPCR 
RNA was extracted from iPSC and fibroblasts using the Nucleospin RNA kit (Macherey-Nagel, 
#740955.250), and 500 ng cDNA synthesised with the Maxima First Strand cDNA Synthesis Kit 
(Thermo Scientific, #K1641). 20 µL PCR reactions contained 10 µL SybrGreen (Thermo Scientific, 
#K0222), 3 µL MQ water, 1 µL of 10 µM forward primer, 1 µL of 10 µM reverse primer (Table 12), 
and 5 µL (5 ng) of template. Three technical replicates of each sample and negative (water) template 
controls were included. Human fibroblasts, a differentiated cell type, were used as a control against 
pluripotency. The transcription factors Sox2, Oct4 and Nanog were chosen as pluripotency markers 
due to their role in maintaining pluripotency, and their validity and widespread use in literature.  
PCR amplifications were carried out with a CFX Touch Real Time PCR Detection system (BioRad) 
for 7 minutes at 95 °C followed by 40 cycles of 95 °C for 10 seconds, 60 °C for 30 seconds and 72 °C 
for 20 seconds. The program ended with a cooling step of 10 seconds at 40 °C. A standard curve for 
each primer pair with mixed serial cDNA dilutions of 10 ng/ µL to 0.156 ng/ µL was included as an 
efficiency control. Cycle threshold (Ct)- values were automatically calculated by Bio-Rad CFX 
Maestro (v 4.1.2433.1219) for each sample and mean Ct values were calculated for three technical 
replicates of each cell line.  
mRNA expression values were normalised to the GAPDH internal control to correct for any 
differences in RNA quantity, quality, and cDNA synthesis efficiency. Changes in relative mRNA 
expression were calculated using the ∆∆Ct (2-ΔΔCT) method (Livak & Schmittgen 2001). Graphs were 
plotted using GraphPad Prism 8.4.1 (GraphPad Software) with data presented as mean ± standard 
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deviation (SD). The significance of differences between means was tested using a one-way ANOVA 
and Tukey post-hoc test for multiple comparisons, with p<0.05 being significant.  
Transcript Forward primer sequence 
 (5’ → 3’) 
Reverse primer sequence  
(5’ → 3’) 
Sox2  GCCCTGCAGTACAACTCCAT TGCCCTGCTGCGAGTAGGA 
Nanog  CTCAGCCTCCAGCAGATGC TAGATTTCATTCTCTGGTTCTGG 
Oct4  TTGGGCTCGAGAAGGATGTG  TCCTCTCGTTGTGCATAGTCG 
Gapdh  cgctctctgctcctcctgtt ccatggtgtctgagcgatgt 
Sars2 TTGGTCCTACGTTCCTCCCA GAGAAAACTGGCTTGTCTCCG 
Table 12. Primers used for RT-qPCR of pluripotency markers and Sars2 in iPSC and fibroblasts 
2.14 Western blot 
2.14.1 Protein extraction  
iPSC and fibroblast cell pellets were lysed with 40 µL RIPA-buffer (Cell Signaling, #9806) 
supplemented with 10 µL/ml of Halt™ protease inhibitor (Thermo Scientific, #10137963). Cell 
lysates were incubated on ice for 10 minutes, centrifuged at 12000 x g for 10 minutes at 4°C, and 
supernatant collected. Protein concentration was quantified with the Pierce™ BCA Protein Assay Kit 
(Thermo Scientific, # 23225), using Bovine Serum Albumin (Biowest, #P6154) samples as a standard, 
with concentrations ranging from 0.25 mg/ml to 10 mg/ml. 
2.14.2 SDS-PAGE electrophoresis and blotting  
10 µg of protein sample was added to 1:3 of the total volume 4 x Laemmli loading buffer (BioRad, # 
1610747) containing 10 % β-mercaptoethanol (BioRad, #1610710) filled to 30 µL with MQ water. 
Samples were loaded on a 10 % stain free 31 gel Mini-PROTEAN-TGX (BioRad # 456-8033) gel, 
with 1 X running buffer (0.3 % Tris, 1.44 % Glycine, 0.06 % SDS) (Thermo Scientific) with Precision 
Plus Protein™ Dual Color Standards (BioRad, #1610374) as the size ladder. Samples were first run 
for 10 minutes at 110 V and then at 125 V for 1 hour 30 minutes.  
 
Proteins from SDS-PAGE were transferred onto a 0.45 µM nitrocellulose membrane (Bio Rad, 
#1620234) by semi-dry blotting using the Trans-Blot Turbo transfer system (Bio Rad). The 
membranes were blocked in 5 % milk (Valio) in TBS–Tween 20 (0.1 %). Immunoblotting was done 
with the indicated primary antibodies (Table 13) and the corresponding secondary antibodies anti-

















Rabbit PA5-31473 Thermo 
Scientific 
58 1:2500 
β-actin Cytoskeleton Mouse sc-47778 Santa-Cruz 45 1:1000 
Table 13. Primary antibodies used in Western blotting of iPSC 
Signal detection was done using enhanced chemiluminescent substrate enhanced luminal & peroxide 
solution (BioRad) and Molecular Imager ChemiDoc XRS+ with ImageLab software (BioRad). 
ImageLab Software 6.0.1 (BioRad) was used to quantify the bands. Relative band intensities were 
normalized to loading control β-actin.  
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3. Results  
The project workflow (Figure 6)  involved creating genome-edited iPSC lines to model a patient-
specific splicing variant c.1347 G>A in SARS2 causing early-onset progressive spastic paresis. First, 
non-allele specific sgRNAs were tested for gene modification efficiency in HEK293 cells. Based on 
their cleavage ability, two crRNAs for CRISPR-Cas9 RNP complexes were chosen and corresponding 
ssODNs designed to make a knock-in mutation in a healthy iPSC line HEL 24.3. Cell lines were 
created from electroporated cell populations with the best gene modification efficiency and estimated 
HDR rates. The editing and HDR efficiencies of the two crRNAs were compared between cell 
populations and cell lines, and potential off-target Cas9 cleavage loci screened in the two genome-
edited disease model cell lines to test the precision and quality of the genome editing. Pluripotency 
markers were measured for iPSC quality control. SARS2 expression at the gene and protein levels 
were measured to compare the genome-edited mutant to the patient and wild type iPSC lines, and 
thereby the ability of the genome-edited lines to recapitulate the effects of the patient mutation. The 
individual results will be discussed next. 
            
Figure 6. Workflow of the creation of genome-edited cell lines in this thesis. The method of clonal 
cell line creation used in this project is adapted from the method reported by Bruntraeger, Byrne, 
Long and Bassett (2019). The method is based on the delivery of a ribonucleoprotein complex (RNP 
complex) and single-stranded donor oligonucleotide (ssODN) repair template delivery into iPSC by 
electroporation to create clonal cell lines. The electroporated cell pools were screened for genome 
editing efficiency using a T7 Endonuclease Assay (NE Biolabs) that recognises and cleaves the 
insertions/deletions (INDELs) in the DNA made by Cas9. Approximately 500-1000 cells from cell 
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pools with the highest genome editing efficiency (DNA cleavage) were seeded on a 10 cm tissue 
culture dish at a low density to create clonal cell populations. Colonies were then manually picked and 
expanded, and duplicate plates of clones were made for cryopreservation and primary genotyping.The 
clones with the desired edit for the SARS2 c.1347 G>A variant were then thawed, expanded, re-
genotyped and quality controlled.  
3.1 Two out of four crRNA were chosen for iPSC electroporation based on 
gene modification efficiency in HEK293 cells 
Four non-allele specific sgRNAs were designed to test transfection efficiency in HEK293 cells with 
the jetPRIME transfection protocol. Their gene modification efficiencies were tested using the T7-
endonuclease assay. crRNA 1 and 4 had gene modification efficiencies of approximately 1.17% and 
15.4% as estimated by ImageLab software band intensity analysis respectively. crRNA 2 and 3 had 
gene modification efficiencies of less than 1%. crRNA 1 and 4 had the highest GFP-positivity 
suggesting transfection efficiency and successful entry of gRNA into nuclei. crRNA 1 and 4 also 
produced the highest T7 endonuclease assay gene modification efficiency scores, suggesting Cas9 
cleavage (Figures 7 A 1 and 2.). crRNA 1 and 4 were chosen for electroporation into iPSC based on 
their higher efficiencies of DNA cleavage in HEK293 cells as compared to minimal DNA cleavage in 
the other two crRNAs (efficiencies summarised in Figure 7 B and Table 14). In iPSC electroporation, 
crRNA1 is referred to as crRNA1 and crRNA4 as crRNA2.  
                    A 1.        A 2.  
                       









                
Figure 7. T7 results for sgRNA 1-4  in HEK293 cells. (A) Successful transfection with sgRNA 1 (1) 
and 4 (2) respectively showing GFP-intensity as detected by Life Technologies EVOS® FL-electro 
fluorescence microscope 24 hours after transfection. The scale of the ruler is 400 µm. (B) Gene 
modification efficiency is shown by the intensity of cleaved bands and the percentage of DNA 
cleaved on a 2% agarose gel, as estimated by ImageLab software band intensity analysis. The two 
sgRNAs with the highest T7 cleavage results (1 and 4) were chosen for iPSC electroporation. The 
lanes in between the tested sgRNAs 1, 2 , 3 and 4 represent negative H2O controls.  
sgRNA Gene modification efficiency Sequence  
1 1.17% GGAGCTGCAGTTTGCCCACA 
2 0.73% TGCAGTTTGCCCACACGgtg 
3 0.71% gctgtgcgggcctcacCGTG 
4 15.4% ctgtgcgggcctcacCGTGT 




3.2 iPSC electroporation 
3.2.1 Gene modification efficiencies in the electroporated cell populations 
Three separate electroporations were done for each of the two crRNAs to ensure the development of 
least one viable cell pool for each crRNA (crRNA 1 and 2). One pool of each was supplemented with 
10 µM Alt-R HDR enhancer (IDT, #1075915), one with 20 µM, and one without the supplement, to 
enhance HDR while also enhancing cell survival through electroporation. Since the HDR enhancer is 
diluted in 3 mM DMSO and is toxic to cells, concentration titration of the HDR enhancer was done to 
maximise chances of survival in the electroporated cell pools, and fresh cell culture medium without 
HDR enhancer was changed 24 hours post-electroporation. The HDR enhancer also acted as a NHEJ 
inhibitor to boost HDR. The presence or concentration of HDR enhancer did not affect cell survival, 
as observed by confluency 24 hours post electroporation. Additionally, a p53 dominant negative 
plasmid was electroporated along with the CRISPR-Cas9 RNP complex to increase the survival of 
iPSC with DSBs and thereby increase genome editing efficiency.   
The three electroporated pools for each of the two crRNAs were each passaged 1:3 following 
expansion to 80% confluence post-electroporation. Genomic DNA from cell pools was PCR-
amplified, and the T7-endonuclease assay tested gene modification efficiency. The electroporated 
pools with the highest gene modification efficiencies chosen for subcloning were 8.45% and 13% for 
crRNA 1 and 2 respectively (Table 15). These cell pools with the highest efficiencies chosen for 
cloning and subcloning were the ones supplemented with HDR enhancer (Figure 8).  
 
A.       B. 
          
Figure 8. T7 results in electroporated iPSC pools. (A) Gene modification efficiency is shown by 
the intensity of cleaved bands and the percentage of DNA cleaved on a 2% agarose gel. 1. refers to 
iPSC pool electroporated with crRNA1 supplemented with 10 µM Alt-R HDR-enhancer (IDT), 2. 
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refers to one supplemented with 20 µM HDR-enhancer, and 3. the cell pool not supplemented with 
HDR-enhancer. (B) Results interpreted the same manner for crRNA2.   
crRNA T7 gene 
modification 
efficiency 










13% ctgtgcgggcctcacCGTGT Reverse ggg 
Table 15. Summary of electroporated pools chosen for subcloning. Gene modification efficiencies 
in electroporated iPSC pools chosen for subcloning based on T7-assay. crRNA 1 supplemented with 
10 µM HDR enhancer and crRNA 2 pool supplemented with 10 µM HDR enhancer were chosen for 
subcloning considering their T7 gene modification scores. They were chosen for their higher gene 
modification efficiencies and the highest probability of containing cells with the knock-in mutation. 
3.2.2 ssODN integration and HDR efficiency in the electroporated pools  
Overall HDR efficiency in the three electroporated cell pools for each crRNA was estimated using a 
bioinformatic tool ICE CRISPR analysis tool version 2 from Synthego (Hsiau et al., 2018). Increasing 
the concentration of Alt-R HDR enhancer did not produce higher HDR efficiency. Overall, crRNA 2 
yielded higher percentages of indels and ssODN integration efficiencies than crRNA 1. Especially the 
crRNA 2 pool that was supplemented with 10 µM of the commercial Alt-R HDR enhancer (IDT) had 
the highest indel percentage (27%) and KI-score (10% of cells with the desired KI). The highest 
concentration of HDR enhancer used (20 µM) did not yield better results for crRNA 2 but improved 
the KI-score slightly for crRNA 1 raising KI-score to 1, whereas it was 0 with lower concentrations 
(summarised in Figure 9). crRNA 2 was designed as a reverse sequence, with the cut site to the 
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Figure 9. Sequencing of electroporated iPSC pools and efficiency of NHEJ and HDR. (A) 
Chromatograms of the electroporated pools from (1) crRNA1 and (2) crRNA2 used as input for the 
ICE CRISPR analysis tool. The blue arrows show the intended mutation site. (B) ICE CRISPR 
analysis tool output results of INDEL percentage and KI-score shows estimates of INDEL percentage 
and proportion, and ssODN integration in the electroporated iPSC pools. Electroporated pool crRNA2 
supplemented with 10 µM Alt-R HDR enhancer (IDT) showed the highest INDEL percentage (27%) 
and knock-in score (10%). crRNA 1 pool with 10 µM Alt-R HDR enhancer had an indel score of 1 
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 3.3 Clonal cell line creation 
3.3.1 Rates of NHEJ and HDR in the clonal cell lines  
For the cloning step of creating the clonal cell lines, 1-2 mm diameter colonies of the appropriate 
morphology (Figure 10) were picked eight days post subcloning. 72 colonies were picked for 
crRNA1, and 96 colonies for crRNA2. Out of these, 64 colonies of crRNA1 and 85 colonies of 
crRNA2 survived for expansion and cryopreservation. Genomic DNA from expanded cells was PCR-
amplified and sequenced. 48.44% of crRNA1 clones and 67.06% of crRNA2 clonal cell lines 
contained DNA cleavage in SARS2 exon 14. 1.56% and 1.18% of clones for crRNA 1 and 2 
respectively were heterozygotes for the mutation (summarised in Table 16).  
                               
Figure 10. iPSC colonies 8 days post subcloning. Light microscope image showing a colony on the 
left with ideal morphology for colony picking to create clonal cell lines (clear, round edges, uniform 
in shape and texture, 1-2 mm in diameter) suggesting origin from a single cell. The colony on the 
right is uneven in shape, and therefore not suitable for colony picking.  
crRNA Wild type (no 
editing) 







1 32/64 (50%) 31/64 (48.44%) 0 0 1/64 (1.56%) 
2 25/81(29.41%) 57/85 (67.06%) 0 2/85(2.35 %) 1/85 (1.18%) 
Table 16. Genome editing- and HDR efficiencies in CRISPR-Cas9 edited clonal iPSC lines 
created from crRNA 1 and 2. Presented as percentages of total number of clonal cell lines expanded 
from picked colonies. ‘Wild type’ cell lines contained no editing despite undergoing electroporation, 
NHEJ clones refer to clones that underwent double-strand break correction by NHEJ, NHEJ clones 
with PAM change to clones that underwent NHEJ along with the PAM change correspondent to the 
crRNA, HDR clones refer to clones that underwent ssODN integration via the HDR pathway of 
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double-stranded break repair, and heterozygotes refer to clones containing the c.1347 G>A mutation 
in one allele only.  
3.3.2 Two SARS2 c.1347 G>A knock-in clonal iPSC lines were created 
2 out of 85 clonal cell lines created with crRNA 2 contained the c.1347 G>A mutation indicating both 
cleavage by Cas9 and ssODN integration through the HDR pathway (summarised in Table 15). These 
two clonal iPSC lines are named KI 1 and KI 2. The KI 1 and KI 2 cell lines contain the same disease 
mutation as the patient cell line HEL 204.6, as shown by their DNA sequences. TOPO-cloning of the 
DNA fragments and re-sequencing of an expanded cell population confirmed homozygous knock-in 
mutations. These two knock-in cell lines were used for subsequent quality control analyses, alongside 
two wild type (WT) lines that underwent electroporation, the parental cell line HEL 24.3, patient iPSC 
line HEL 204.6, and one cell line that underwent DSB correction by NHEJ in one allele resulting in a 
frameshift (Figure 11).  
                                 
Figure 11. SARS2 Sanger sequencing results. Comparison of chromatograms between the parental 
cell line HEL 24.3, wild type (WT) (electroporated but not genome edited), patient cell line HEL 
204.6, the two edited iPSC lines demonstrates the successful editing of c.1347 G>A mutation by HDR 




3.3.3 iPSC morphology of wild type, KI and patient cells  
The two KI, patient, and wild type iPSC grew at a similar rate and had typical iPSC morphology. The 
colony in Figure 12. A is an example of an ideal iPSC morphology: round colonies, clear borders and 
even surface. Further analyses of cell morphology could be important in explaining disease 
mechanisms modelled by the genome-edited iPSC lines.  
A                                                                            B  
       
C 
 
Figure 12. Light microscope images of iPSC colonies.  (A) KI 1 passage 11 (B) KI 2 passage 11 (C) 
Parental HEL 24.3 passage 34. The ruler scale is 200 µm.  
3.4 No off-target CRISPR-Cas9 cleavage was present in the two knock-in 
iPSC lines 
Quality control analyses involved bioinformatic analyses of potential off-target genome editing by 
CRISPR-Cas9. Off-target regions were sequences similar to the complementary SARS2 region 
targeted by crRNA 2. Mismatches between crRNA-DNA pairing can be well tolerated at some similar 
loci and result in Cas9 cleavage. The two clonal cell lines KI 1 and KI 2 created with the RNP 
complex containing crRNA 2 underwent Sanger sequencing according to section 2.7 for the screening 
of off-target genome editing by SARS2 crRNA 2 (ctgtgcgggcctcacCGTGT). Table 17 summarises the 
51 
 
CFD off-target scores of the 7 most significant potential off-target loci for crRNA 2, and PCR primers 
from CRISPOR Batch Gene Targeting Assistant (http://crispor.tefor.net/) and amplicons from in-
silico PCR (https://genome.ucsc.edu/cgi-bin/hgPcr). In total, CRISPOR Batch Gene Targeting 
Assistant estimated 69 off-target regions. No off-target Cas9 cleavage was detected in the regions 
(Figure 13) by Sanger sequencing and NCBI BLAST® (Basic Local Alignment Tool, Nucleotide 
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Table 17. Analysis of CRISPR-Cas9 off-target effects. Top hits for potential off-target areas of 
SARS2 crRNA2 (ctgtgcgggcctcacCGTGT) and their CFD-scores, PCR primers for sequencing cell 
lines KI 1 and KI 2, and amplicon sequences. 
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Figure 13. Sanger sequencing results of the off-target regions in genome-edited knock-in cell 
lines KI 1 and KI 2. No Cas9 cleavage or DSB correction by NHEJ was present as shown in the 
chromatograms for SPNS3, RP11, LHPP, AC091150.1, ADARB2-AS1, BLK and C15orf6. All the 
sequences corresponded to the reference sequence (NCBI BLAST®).   
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3.5 The genome-edited iPSC lines expressed pluripotency markers  
iPSC need to remain in a pluripotent state to ensure their ability to be induced to differentiate into any 
cell type of the three germ layers (endoderm, mesoderm, ectoderm) for the purpose of disease 
modelling. The relative expressions of transcription factors Sox2, Oct4 and Nanog were significantly 
different (P < 0.01) between the iPSC lines and the wild type fibroblasts that were tested as a negative 
control for pluripotency (Figure 14). The expression of pluripotency markers in KI 1 and KI 2 
demonstrates their pluripotency and thereby status as (induced) pluripotent stem cells.  
                
                                        
Figure 14. Relative expression of pluripotency markers in the compared iPSC lines. Relative 
expression of the pluripotency-related transcription factors Sox2, Oct4 and Nanog. Wild-type 
fibroblast as a negative control for pluripotency. Normalisation to GAPDH. Data shown as mean ± 




3.6 The genome-edited iPSC lines modelled the patient’s SARS2 protein 
deficiency and mRNA expression  
To test the comparability of the genome-edited knock-in iPSC lines to the patient and parental/wild 
type lines, SARS2 protein level was measured by Western blot, and relative Sars2 mRNA expression 
measured by RT-qPCR. SARS2 protein level was severely decreased in the patient and genome-
edited iPSC, as shown by immunoblotting (Figure 15 A) and quantification of band intensity (Figure 
15 B). The genome-edited iPSC lines modelled the patient’s decrease in SARS2 protein level, with a 
decrease in intensity to 14% of normal compared to the parental in HEL 204.6, 15% in KI 1, 20% in 
KI 2, and 30% in the NHEJ clone. However, there was a marked difference in band intensity between 
the healthy controls (parental and wild type), which may be due to undiscovered off-target genome 
editing or other quality anomalies. Although KI 1, KI2 and patient iPSC showed a decreased Sars2 
mRNA expression level, the isogenic lines KI 1 and KI 2 did not statistically significantly model the 
patient’s significant decrease in Sars2 mRNA expression compared to parental and wild type. Again, 
there were statistically significant differences in Sars2 expression between the parental and other wild 





            
 
B  
                                             
Figure 15. SARS2 Western blot results compared between control and patient cell lines. (A) 
Immunoblotting of SARS2 shows a marked decrease in the mitochondrial protein in the patient and 
knock-in mutants as compared to the healthy parental and wild type lines. The NHEJ clone shows a 
lesser decrease in protein than the KI mutation causing a frameshift. (B) The relative protein 
intensities normalised to loading control β-actin show a marked difference between the parental and 
wild type cell lines, and a decrease in intensity to 14% of parental in HEL 204.6, 15% in KI 1, 20% in 
KI 2, and 30% in the NHEJ clone (n=2 technical replicates per cell line). 
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Figure 16. The relative mRNA expression of Sars2 was significantly different between the HEL 24.3 
parental control and the NHEJ clone and fibroblast, but not between HEL 24.3 and the patient cell line 
HEL 204.6 or the two KI clones. Normalisation to GAPDH. Data shown as mean ± SD. One-way 





The overarching aim of this project was to create genome-edited iPSC lines using CRISPR-Cas9 to 
model a patient-specific splicing variant c.1347 G>A in SARS2 that causes severe childhood-onset 
progressive spastic paresis. All 19 mt-aaRS have been associated with disease-causing mutations 
causing a wide variety of phenotypes, presenting in disparate ways in different patients. Disease 
mechanisms for many are not known, and isogenic iPSC lines are a valuable tool for studying the 
molecular and cellular mechanisms of mt-aaRS related mitochondrial diseases.  
Two different CRISPR-Cas9 ribonucleoprotein complexes and associated single-stranded donor 
oligonucleotides as repair templates were used to make a knock-in mutation in wild type iPSC. Two 
genome-edited iPSC cell lines that accurately model the patient genotype were created by one of the 
ribonucleoprotein complexes. The established iPSC line HEL24.3 was used as the parental cell line, 
as it is reported to express pluripotency markers Oct4, Sox2 and Nanog, and is able to differentiate 
into cells of all three germ layers by a teratoma assay, and has a normal karyotype (Trokovic et al., 
2015). Additionally, the success and precision of the genome editing in the two genome edited disease 
models was established. The genome editing and HDR efficiencies by the two crRNAs used in the 
RNP complexes were investigated. The quality of the genome-edited iPSC lines in terms of 
pluripotency markers was measured, and thereby validity of the models to be used in differentiation to 
the affected cell type and studies of disease mechanisms. To preliminarily test the ability of the 
isogenic control iPSC lines to model the patient iPSC lines, SARS2 protein level and relative mRNA 
expression were measured.  
4.1 The design and success of the CRISPR-Cas9 RNP complex 
Out of two crRNAs designed to create genome edited knock-in iPSC lines, one successfully created 
two iPSC lines to model the patient mutation. The crRNA in the RNP complex immediately cleaves 
DNA, and the concentration of the homologous recombination template is highest immediately after 
electroporation, but rapidly declines over 24 hours reducing off-target effects (Kim et al., 2014). RNP 
complex delivery is less stressful to stem cells and more efficient than plasmid transfection (Kim et 
al., 2014). Many studies have shown that the most efficient and customisable for iPSC knock-in 
genome editing is CRISPR-Cas9 RNP with a repair template (reviewed in Bollen et al., 2018). 
Electroporation is the best transfection method for iPSC, which are difficult to transfect and edit 
compared to tumour cell lines or mouse embryonic stem cells (reviewed in Ihry et al., 2018). 
Electroporation has been reported to be most successful with Neon Electroporator (Life Technologies) 
that was used in this project, and Nucleofector (Lonza), which are the most commonly used 
electroporators (Li et al., 2015; Ran et al., 2013).  
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A wide range of monogenic, complex, chromosomal and epigenetic disorders occurring in various 
stages of life have been successfully modelled with human pluripotent stem cells (reviewed in Avior, 
Sagi & Benvenisty, 2016). The small phenotypic differences between cells differentiated from patient 
and control iPSC may reflect unpredictable genetic variation (differing in millions of SNPs in each 
genome) and non-genetic variation between individual iPSC lines, masking the disease phenotype. 
Experimental variation exists in cell differentiation and subsequent passaging. P53 mutations inhibit 
CRISPR-Cas9 editing and have toxic effects in human pluripotent stem cells. It has been reported that 
there is a reduced efficiency of precise editing in human pluripotent stem cells with a wild type p53 
gene (Ihry et al., 2018). These may be confounding and limiting factors in the success of disease 
modelling. However, later passage iPSC have less epigenetic memory, which may be advantageous 
for modelling genomic mutations (Soldner & Jaenisch, 2012; Hockemeyer & Jaenisch, 2017).  
The conditions of cell culture and genome editing are crucial to editing success. In this study, 
supplementing electroporated iPSC with 10 µm HDR enhancer produced the best rate of HDR and 
overall genome editing efficiency without affecting cell survival as seen by the number of attached 
cells 12 and 24 hours post-electroporation. The addition of a broad-spectrum antibiotic to avoid 
infections in cell culture did not affect cell survival or morphology at any stage of clonal cell line 
creation. iPSC were grown on a chemically defined vitronectin coating. Artificial cell culture 
conditions may affect the growth and characteristics of cells (Chen et al., 2011). iPSC of passage 32 
were used for electroporation. Electroporation causes additional stress to iPSC, and stronger cells that 
divide quicker have an advantage in survival. A disadvantage of this is the potentially higher number 
of mutations that are harboured by higher passage cells. The addition of Rho-kinase (ROCK) inhibitor 
Y-27632 suppresses anoikis during disaggregation of human embryonic stem cell colonies and 
increases single-cell survival in stem cells (Watanabe et al., 2007). The addition of ROCK-inhibitor to 
cell culture medium before and after electroporation can contribute to iPSC survival in genome 
editing.  
The rates of NHEJ and HDR in the electroporated iPSC pools were estimated based on Sanger 
sequencing input into the ICE CRISPR analysis software (Synthego) that estimates the proportion of 
each DNA repair mechanism. Based on these estimates, the occurrence of NHEJ in double-strand 
DNA break repair is higher than that of HDR, matching the results of previous studies (Kim et al., 
2014; Bassett, 2017). The predicted crRNA success and the results from electroporation varied in 
several ways. On-target scores from the Benchling web tool, which represented the probability of 
Cas9 binding to the region targeted by the crRNA, suggested that crRNA1 and crRNA2 would have 
similar efficiency. However, crRNA 2 outperformed crRNA1 upon transfection to HEK293 cells and 
iPSC. CRISPOR’s CFD (Cutting Frequency Determination) score ranked the uniqueness of a gRNA 
in the reference genome, considering the off-target cleavage fraction of the gRNA. Off-target regions 
should be as far away as possible from the PAM sequence to avoid direct interference with the 
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intended edit. CFD scores suggested that crRNA1 would be slightly more specific and efficient than 
crRNA2, which was not the case since the two knock-in cell lines were created with crRNA2. 
Additionally, after iPSC electroporation, the percentage of indels varied between T7 assay and 
estimates by the software ICE CRISPR analysis tool. This may be explained either by incomplete 
recognition of cleaved DNA by T7 endonuclease, or computational inaccuracies. However, the ICE 
CRISPR tool provided important information about the percentage of knock-ins, which was crucial 
for this project in choosing the right cell population for subcloning. A restriction enzyme could have 
been used to recognise the knocked-in point mutation more efficiently and reliably, but additional 
mutations next to the patient mutation were not made to avoid unwanted effects on the disease model. 
The use of a restriction enzyme would have eliminated the need for sequencing and indirect in-silico 
analysis. There are several possible reasons for the lower occurrence of HDR that will be discussed.  
It was important to design multiple crRNAs, in this case four, and test the gene modification 
efficiencies on HEK293 cells. This was done to test crRNA efficiency under laboratory conditions, 
which may differ from computational efficiencies. Two of the four crRNAs produced favourable gene 
modification efficiencies in HEK293 cells based on GFP-positivity and T7-assay results. The 
laboratory results and crRNA on-target and off-target scores from two different in silico tools 
(Benchling, CRISPOR) were considered before iPSC electroporation.  
The success and precision of genome editing depend on choosing an appropriate site, crRNA and 
ssODN design, and Cas9 activity. The better HDR performing crRNA 2 was designed as a reverse 
sequence, with the cut site to the mutation being just 1 nt. This could suggest that an RNP complex 
with the reverse crRNA sequence with the cut site as close as possible to the mutation produced the 
best results in terms of NHEJ and HDR efficiency. Previous studies have found that a DSB occurring 
close to the intended mutation site correlates with gRNA efficiency (Ran et al., 2013). While in this 
project the two crRNAs were designed in different orientations, Cas9 can detect a PAM sequence in 
the sense or antisense directions, so crRNA orientation should be of trivial importance (Wang et al., 
2016a). While a p53 dominant negative plasmid was included in the electroporations to lower chances 
of toxic effects of p53 on cells with DSBs, its use was not necessary. The protein from the plasmid is 
expressed too slowly compared to the RNP-mediated DNA cleavage, resulting in the risk of plasmid 
integration into the target genome. Plasmid transfection can also be cytotoxic for some cell types 
(Kim et al., 2014).  
4.2 Efficiency and quality of genome editing in the two successfully created 
genome-edited knock-in iPSC lines  
In this project, the use of CRISPR-Cas9 RNP complex for genome editing and manual colony picking 
method of cell line creation produced favourable genome editing results for the purpose of disease 
modelling. Two genome-edited cell lines to model the patient mutation c.1347 G>A in SARS2 were 
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successfully created from the cell population electroporated with crRNA 2 supplemented with 10 µM 
Alt-R HDR enhancer. This amounts to 2.35% of all colonies that were expanded originating from that 
cell population. From both the crRNAs, only one heterozygous clone was created. The Sanger 
sequencing and TOPO-cloning results suggest the ssODN incorporated into the genome in the desired 
way for a homozygous SARS2 c.1347 G>A mutation. Like in the electroporated pools, there was a 
higher percentage of DNA breaks repaired by NHEJ than by HDR. The overall genome editing 
efficiency was higher in crRNA 2 than crRNA 1. Out of the clonal cell lines created, only 50% were 
wild type for crRNA 1 and 29.41% were wild type for crRNA2. Although both NHEJ and HDR 
efficiencies were lower than in previous studies, two pluripotent isogenic iPSC lines with 
homozygous recombination without off-targets were successfully created from picking only 85 
colonies. Saarimäki-Vire et al. (2017) reported 5.3% of iPSC clones having heterozygous or 
homozygous recombination and correction of the patient mutation with the repair template. Low 
toxicity of RNP complex electroporation and further ensuring cell survival of electroporated cells by 
manual colony picking over FACS possibly also contributed to the successful outcome in genome 
editing. While manual colony picking is less reliable than automatic cell sorting for creating clonal 
cell lines, careful sequencing of the clones KI 1 and KI 2 determined that they likely originate from a 
single cell (Bruntraeger et al., 2019).  
In most cell types, NHEJ is massively favoured over HDR, with HDR only being likely in the late-S, 
G2 phases of the cell cycle when DNA replication is complete and sister chromatids are available to 
serve as repair templates. HDR is the least error-prone DSB repair strategy but harnessing it in 
experimental setups is difficult and designs are often low in editing efficiency (Shrivastav et al., 
2008). Successful creation of knock-in mutants exploiting the HDR pathway is restricted to 
proliferative cells in a logarithmic growth phase without growing to full confluency. Mutagenesis by 
NHEJ varies between experimental setups but can be as high as 80-90% (Bassett, 2017). Cho et al. 
(2013) reported indel frequencies of up to 33% in human cells using CRISPR-Cas9. Genome editing 
efficiencies and especially HDR frequency tend to be lower in embryonic stem cells and iPSC than in 
cancer cell lines (Hockemeyer & Jaenisch, 2017). This phenomenon may also explain the lower rate 
of HDR compared to NHEJ rate in this project.  
HDR can be supported by NHEJ inhibition or HDR enhancement. However, HDR enhancement is 
generally preferred due to cytotoxic side effects of NHEJ inhibition. Jayavaradhan et al. (2019) 
showed in K562 cells (a human immortalised myelogenous leukaemia cell line) that Cas9-DN1S 
fusion proteins (a dominant-negative mutant of 53BP1 bound to Cas9 nucleases) significantly blocked 
NHEJ events locally at Cas9 cut sites and improve HDR frequency Wang et al. (2017) reported that 
using a doxycycline-inducible Cas9 transgene on a PiggyBac transposon resulted in INDEL 
frequencies of 40-50% and HDR frequencies of 10-20%. Skarnes, Pellegrino & McDonough (2019) 
demonstrated that the added effects of a cold shock, small molecule HDR enhancer, and chemically 
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modified ssODN shift DNA break repair to favour HDR, resulting in HDR in 70% of unselected 
human iPSC. Combining cell cycle synchronisation in the G2/S phase with timed RNP delivery can 
increase HDR success by increasing nuclease activity in the HDR favourable phase of the cell cycle 
(Bollen et al., 2018). Using a paired nickase approach, Bothmer et al. (2017) observed a shift in repair 
outcome distribution and a specific signature of repair outcomes for two different overhang structures. 
D10A-induced dual-nicking results in a 50 overhang that more frequently engages HDR than N863A-
induced 30 overhangs. Yu et al. (2019) reported that using a Cas9 ribonucleoprotein with 5’-modified 
double-stranded DNA donors with 50 bp homology arms lead up to a fivefold change in HDR rates at 
various locations in human stem cells. While the design of silent mutation outside the SNP of interest 
can decrease the chance of re-cutting by Cas9, the additional silent SNPs may affect protein 
translation efficiency (Bassett, 2017). The use of nickases to create single-strand breaks, modified 
Cas9 proteins, or design of silent mutations can all help lower off-target genome editing depending on 
the target locus and cell type. Most testing has been done on cancer cell lines (Hockemeyer & 
Jaenisch, 2017).  
Rates of HDR to introduce disease-associated mutations can be increased by using an ssODN repair 
template over dsDNA due to somewhat different DNA repair mechanisms. ssODNs produce short 
conversion tracts preferentially through synthesis-dependent strand annealing, enabling efficient DNA 
repair without sacrificing genomic stability (Kan et al., 2017). Additionally, ssDNA has higher 
recombinogenic tendencies (Bassett, 2017). Zhang et al. (2017) found that the supplementation with 
both CCND1, a cyclin that functions in G1/S transition, and nocodazole, a G2/M phase synchronizer, 
doubles HDR efficiency to up to 30% in iPSCs. Results from other studies support the use of 
reversible chemical inhibitors to enhance HDR. Supplementation of stem cells and iPSC with ABT to 
arrest cells in G2 phase increases on-target genome editing and donor incorporation, compared to cells 
in G1 phase (Yang et al., 2016). Controlled timing by CRISPR-Cas9 delivery with nocodazole 
synchronization and high concentration of Cas9 RNP at 100 ρmol increased homology directed repair 
up to 31% without affecting cell morphology in culture (Lin et al., 2014). Yang et al. (2016) also 
showed that a 16-hour treatment with 1μg/ml Nocodazole and one hour in Nocodazole-free medium 
showed significant G2/M phase enrichment in 80% of cells, while 58.1% of untreated cells were in 
G1 phase. These results suggest that rates of HDR can be enhanced by timed delivery of CRISPR-
Cas9 complex, and chemically arresting cells in G2 phase can enhance HDR without being 
significantly harmful at least for disease modelling purposes. 
When considering in vivo mutation corrections that could be used to correct patient mutations such as 
the one in this project, precision and safety are even more crucial. Yusa et al. (2011) used ZFN with 
piggyBac transposition to make a point mutation (Glu342Lys) in the α1-antitrypsin gene to rescue the 
α1-antitrypsin deficiency in differentiated liver cells in vitro and in vivo. This demonstrates that 
genetic correction of human iPSC can generate clinically relevant cells for autologous transplantation. 
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Concerns about reliability of iPSC and their applicability for therapeutic use have arisen from reports 
about differences in global chromatin structure and gene expression profiles between human iPSC and 
embryonic stem cells. However, they show very few differences in terms of transcriptional programs 
and nucleosome structures (Guenther et al., 2010). Immune responses against Cas9 proteins are 
another hurdle for in-vivo use of CRISPR-Cas9 (Broeders et al., 2020).  
Understanding how to avoid off-target DNA modification by CRISPR-Cas9 is important both for 
fidelity of disease modelling and for clinical applications of edited iPSC like autologous cell 
transplantation. In this project, no off-target indels were present in the likely off-target regions that 
were analysed. Off-target mutagenesis can disrupt endogenous gene function, producing artefacts that 
can be misleading in in vitro experiments, and harmful for clinical use (Frock et al., 2014). Undesired 
mutations in both alleles can also be present in correctly targeted clones created using the Cas9 
nuclease, and Cas9-D10A single and double nickases (Merkle et al., 2015). The advantage of 
CRISPR-Cas9 RNP complexes is their lower rate of off-target mutations than viral-vector based 
CRISPR-Cas9 methods (Argani, 2019). Single and double mismatches are tolerated by Cas9 
nucleases, and off-target sites can harbour up to five mismatches and many were mutagenized with 
frequencies comparable to (or higher than) those observed at the intended on-target site (Fu et al., 
2013). Restricting the time period CRISPR-Cas9 is active, off-target mutagenesis can be lowered 
(Merkle et al., 2015). Some studies have found that reducing the amount of active Cas9 in the cell 
reduces off-target mutagenesis. However, the amount of Cas9 needs to be optimised so that on-target 
cleavage is ensured to a reasonable standard. To decrease off-targets, other studies have pointed to the 
use of Cas9 nickase mutants to create a pair of juxtaposed single-stranded DNA nicks, truncating the 
gRNA sequence at the 5’ end, or using a pair of catalytically inactive Cas9 nucleases fused to a Fok1 
nuclease domain (reviewed in Slaymaker et al., 2016). Based on high-throughput genome-wide 
translocation sequencing, Frock et al. (2015) report that the Cas9D10A paired nickase approach 
suppresses genome-wide off-target cleavage. Limitations in targetability due to restrictions by 
species-specific PAM sequence can be overcome by finding alternative orthologous CRISPR systems 
e.g. SaCas9 and Cpf1, in addition to engineering of Cas9 proteins (Bollen et al., 2018).  
Off-targets can also be minimised by approaching HDR machinery. The composition of the donor 
template can be altered towards favouring a particular DSB repair pathway (Bollen et al., 2018). Non-
specific integration of DNA is minimised by using an ssODN repair template over dsDNA 
(Bruntraeger et al., 2017). Symmetric ssODNs produce more favourable results than asymmetric 
ssODNs (reviewed in Bollen et al., 2018). Base editors are a good alternative for making single 
nucleotide substitutions, due to no genomic cleavage, eliminating the off-target effects. However, 
base editors are limited to certain base substitutions, and are more suited to creating heterozygous 
mutations than homozygous mutations (Rees & Liu, 2018). Since the goal of this project was to create 
a homozygous knock-in mutation, HDR-mediated genome editing remains the most feasible and 
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economical choice for this goal. Considering the error-prone nature of CRISPR-Cas9, karyotyping 
and comprehensive sequencing should be done to screen clones to fully establish the quality of the 
cell line and thereby the validity of the disease model.  
Off-targets in exonic regions may be detrimental to disease modelling. The severity of off-target 
effects in the disease model would depend on the role of the off-target regions in cell health and the 
disease phenotype. The discrepant Sars2 mRNA expression level differences between the parental and 
other wild types could be due to other off-target genome editing not analysed, or technical errors, 
differences in RNA quality, or fluorescence. Similarly, discrepant results in pluripotency marker 
expression could be explained by the presence of differentiated cells in the collected iPSC population. 
However, all cell pellets collected contained no visible differentiated cells and were approximately 
80% confluent on a 35 mm cell culture dish.  
4.3 Questions to be answered using the genome-edited iPSC lines  
All aminoacyl-tRNA synthetases and mitochondrial aminoacyl-tRNA synthetases have the same 
canonical role of charging the appropriate amino acid onto its tRNA (aminoacylation). The use of 
genome-edited and isogenic controls is crucial for studying the heterogeneous defects in 
mitochondrial aminoacyl tRNA-synthetase disorders. The use of isogenic controls and wild types 
provides a more precise approach to investigating and characterising disease phenotypes and 
mechanisms than the more commonly used method of transgenic overexpression, which cannot be 
used to accurately target recessive phenotypes (Bollen et al., 2018). Recent studies on different mt-
aaRS based mitochondrial diseases suggest a categorisation of diseases based on tissue specificity of 
clinical manifestations: 1. Mainly affecting the CNS, 2. Affecting the CNS and another system, and 3. 
Affecting the CNS or another system, and 4. Affecting a system other than the CNS (reviewed in 
González-Serrano, Chihade & Sissler, 2019). Discovering the mechanisms behind mt-aaRS related 
disease phenotypes would help in understanding and categorisation of diseases and thereby 
discovering the functions of the individual mt-aaRS enzymes for targeting treatments.  
The two iPSC lines created in this project modelled the patient’s decrease in SARS2 protein level and 
mRNA expression. This preliminary disease mechanism analysis suggests that the c.1347 G>A 
mutation in SARS2 causes a defect at the protein level leading to reduced SARS2 protein level. In the 
original patient report, Linnankivi et al. (2016) found in the patient fibroblasts a decrease in SARS2 
protein down to 10% of normal. Further, differentiation of the patient iPSC and edited cell lines and 
their isogenic parental controls into motor neurons and characterisation of differential gene expression 
can reveal the neuron-specific effects of the mutation in protein and mRNA levels, development and 
morphology. More specific exploratory disease mechanism analyses include studying more specific 
structures like mitochondrial complexes and analyses of mitochondrial translation. The results could 
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reveal the importance and role of SARS2 in different cell types, which might be a clue to discovering 
disease mechanism pathways. In investigating the mechanism of the SARS2 defect, it is important to 
consider how crucial the SARS2 protein is for iPSC and motor neuron functions and morphology. 
The expression of pluripotency markers Oct4, Sox2, and Nanog suggested that the genome-edited 
iPSC lines were indeed pluripotent stem cells. However, their validity as iPSC models and ability to 
be differentiated into any cell type in the three germ layers (endoderm, mesoderm, ectoderm) to 
investigate the mechanisms of the SARS2 c.1347 G>A mutation in the childhood-onset progressive 
spastic paresis phenotype will need to be further established. This can be done by an in-vitro 
differentiation assay such as embryoid body differentiation where cells are guided to spontaneously 
differentiate, after which markers of each germ layer are analysed with immunocytochemistry. As a 
quality control step in addition to RT-qPCR of the pluripotency markers, immunocytochemistry 
should be used to see the localisation and intensity of pluripotency markers.  
4.4 Conclusions and future perspectives 
A generalised CRISPR-Cas9 platform for iPSC editing is an important method for both basic and 
biomedical research. A highly customisable, highly target-specific and quick to assemble CRISPR-
Cas9 RNP complex can improve the speed and reliability of iPSC-based in vitro disease modelling in 
single-gene disorders of unknown etiology. Manipulating genes enables the characterisation of their 
functions. This could also enable increased precision for in vivo editing in animal models and 
modification of patient cells ex-vivo for autologous transplantation. iPSC as model systems provide 
many advantages over cancer cells, which have long been used as the default cell model system. 
Advantages of iPSC include patient specificity with relevant genotypic background, and 
customisability in that they can be edited and differentiated into disease-relevant cell types to 
elucidate cell type specific disease mechanisms. In this project, two patient-specific genome-edited 
control iPSC lines were successfully and precisely created and partly validated as disease models.  
The remaining challenges of using CRISPR-Cas9 for iPSC-based disease modelling include low 
efficiency in iPSC, iPSC heterogeneity in morphology, and maintenance of pluripotency in culture. In 
vitro culture and genome editing by electroporation could alter genomic stability of the cells 
(Hockemeyer & Jaenisch, 2017). iPSC models can reveal information about cellular and intracellular 
events but are limited in their ability to model more complex phenotypes, for example ones that affect 
whole organs or organ systems. Additionally, cell culture on synthetic growth surfaces may affect 
disease modelling capabilities in known and unknown ways. To optimise CRISPR-Cas9 genome 
editing, more advanced in silico methods are being developed for designing and estimating 
efficiencies of crRNAs and ssODN/ssDNA homologous recombination templates with reduced off-
targets. Other ways of improving gRNA fidelity include engineering gRNA stability and optimising 
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RNP complex chemistries. Considering iPSC culture conditions and CRISPR-Cas9 setup and 
optimisation can improve speed and accuracy of iPSC disease modelling and reporter cell line 
capabilities while maintaining iPSC survival rate and stemness.  
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